International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
ABSTRACT Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published i...
Uložené v:
| Vydané v: | Movement disorders Ročník 33; číslo 8; s. 1248 - 1266 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.08.2018
|
| Predmet: | |
| ISSN: | 0885-3185, 1531-8257, 1531-8257 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | ABSTRACT
Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).
Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.
Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.
Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise‐based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.
Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society |
|---|---|
| AbstractList | Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).
Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.
Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.
Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise‐based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.
Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).OBJECTIVEThe objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.BACKGROUNDThe Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.METHODSLevel I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.RESULTSA total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society.CONCLUSIONSThe options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society. ABSTRACT Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016. Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported. Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise‐based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful. Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016. Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported. A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful. The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society. |
| Author | Seppi, Klaus Barton, Brandon Fox, Susan H. Coelho, Miguel Lim, Shen‐Yang Sampaio, Cristina Katzenschlager, Regina de Bie, Rob M. A. |
| Author_xml | – sequence: 1 givenname: Susan H. surname: Fox fullname: Fox, Susan H. email: sfox@uhnresearch.ca organization: University of Toronto Department of Medicine – sequence: 2 givenname: Regina surname: Katzenschlager fullname: Katzenschlager, Regina organization: Danube Hospital – sequence: 3 givenname: Shen‐Yang surname: Lim fullname: Lim, Shen‐Yang organization: University of Malaya – sequence: 4 givenname: Brandon surname: Barton fullname: Barton, Brandon organization: Jesse Brown VA Medical Center – sequence: 5 givenname: Rob M. A. surname: de Bie fullname: de Bie, Rob M. A. organization: University of Amsterdam – sequence: 6 givenname: Klaus surname: Seppi fullname: Seppi, Klaus organization: Medical University Innsbruck – sequence: 7 givenname: Miguel surname: Coelho fullname: Coelho, Miguel organization: University of Lisbon – sequence: 8 givenname: Cristina surname: Sampaio fullname: Sampaio, Cristina organization: University of Lisbon |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29570866$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1O3DAQxy0EguXjwAtUvrU9BDxOHDu9IfqFBAKp5Ww5yUQ1Teyt7QXtrY_Qcx-vT1IvuwgJtSdb9u__G83MPtl23iEhx8BOgDF-OvXxhMtS8i0yA1FCobiQ22TGlBJFCUrskf0Y7xgDEFDvkj3eCMlUXc_I7wuXMDiTrHdmpDcmfLcuekeN6-nk73FCl2hvow89Bhp9ZzEtKd7bHl2Hf37-ak3EjGJvO-uQhvyFD-_o7bw3CWk2pYAmrTSRDj7Q9A2zOOVbXE7z5KdI_fBc-HVcVcMsPSQ7gxkjHm3OA3L78cPX88_F5fWni_Ozy6IrG-CFQWHqBg1Kw4B30FZtzZnIj3ULpYGBVwJlMwhQFTDOpBxUXymsRM1waJrygLxZe-fB_1hgTHqyscNxNA79ImrOQDEuq6bK6KsNumhzx3oe7GTCUj_NMwOna6ALPsaAg-5sehxuCsaOGphebUznjenHjeXE2xeJJ-m_2I39wY64_D-or95_WSf-AjWvqP0 |
| CitedBy_id | crossref_primary_10_1016_j_parkreldis_2024_106022 crossref_primary_10_1016_j_jare_2025_05_034 crossref_primary_10_3233_JPD_212976 crossref_primary_10_3390_antiox11050810 crossref_primary_10_2217_nmt_2022_0038 crossref_primary_10_1007_s13760_024_02656_0 crossref_primary_10_1016_j_bbadis_2022_166365 crossref_primary_10_3390_brainsci15070666 crossref_primary_10_1123_jab_2019_0253 crossref_primary_10_1007_s10072_024_07599_1 crossref_primary_10_1007_s40267_022_00912_y crossref_primary_10_3233_JPD_212979 crossref_primary_10_1177_1756286420986744 crossref_primary_10_3233_JPD_191712 crossref_primary_10_1080_14656566_2018_1543407 crossref_primary_10_1186_s12979_023_00404_1 crossref_primary_10_1044_2023_AJSLP_23_00062 crossref_primary_10_2217_nmt_2022_0020 crossref_primary_10_3233_JPD_230292 crossref_primary_10_1016_j_parkreldis_2024_107103 crossref_primary_10_1002_brb3_2352 crossref_primary_10_1017_cjn_2022_75 crossref_primary_10_1111_cns_14531 crossref_primary_10_1111_imj_15148 crossref_primary_10_1016_j_neuro_2024_12_003 crossref_primary_10_1016_j_ncl_2024_12_002 crossref_primary_10_1124_molpharm_122_000633 crossref_primary_10_1002_mdc3_12837 crossref_primary_10_3389_fnagi_2023_1114466 crossref_primary_10_3389_fnins_2021_782046 crossref_primary_10_1016_j_ejmech_2023_115475 crossref_primary_10_1124_pharmrev_122_000743 crossref_primary_10_1038_s41598_023_49870_z crossref_primary_10_1016_S1474_4422_21_00249_0 crossref_primary_10_1007_s13760_022_02104_x crossref_primary_10_1371_journal_pone_0244148 crossref_primary_10_1186_s40537_023_00751_2 crossref_primary_10_3390_biom12020228 crossref_primary_10_1136_bmjno_2023_000499 crossref_primary_10_3233_JPD_230384 crossref_primary_10_1080_14737175_2022_2128768 crossref_primary_10_3389_fnins_2021_623317 crossref_primary_10_1016_S0140_6736_23_01429_0 crossref_primary_10_3390_brainsci14121238 crossref_primary_10_1177_17562864241289207 crossref_primary_10_1097_MCG_0000000000001961 crossref_primary_10_3390_jcm14030748 crossref_primary_10_1002_cpdd_1147 crossref_primary_10_33262_ap_v6i3_2_530 crossref_primary_10_5334_tohm_798 crossref_primary_10_3389_fneur_2019_00452 crossref_primary_10_1016_j_arr_2023_102077 crossref_primary_10_1016_j_bbr_2024_115410 crossref_primary_10_1016_j_parkreldis_2021_09_024 crossref_primary_10_1177_08919887211018277 crossref_primary_10_3389_fpsyg_2022_847703 crossref_primary_10_1002_cpt_1374 crossref_primary_10_1080_14728222_2021_1999928 crossref_primary_10_1007_s40265_019_01098_w crossref_primary_10_1055_a_2238_1641 crossref_primary_10_1093_ijnp_pyaf033 crossref_primary_10_1016_j_compmedimag_2024_102488 crossref_primary_10_1021_acssensors_4c00602 crossref_primary_10_1007_s00415_024_12632_6 crossref_primary_10_1016_j_jchemneu_2024_102422 crossref_primary_10_3389_fneur_2025_1650985 crossref_primary_10_3389_fcimb_2025_1455123 crossref_primary_10_7759_cureus_29646 crossref_primary_10_3390_ph11020044 crossref_primary_10_1002_mds_30231 crossref_primary_10_1038_s41531_024_00665_7 crossref_primary_10_3390_pharmaceutics15030770 crossref_primary_10_1155_2022_2073068 crossref_primary_10_1227_neu_0000000000002274 crossref_primary_10_3233_JPD_230277 crossref_primary_10_1002_cpdd_1157 crossref_primary_10_1016_j_exger_2021_111376 crossref_primary_10_1136_bmjno_2024_000793 crossref_primary_10_4103_1673_5374_375299 crossref_primary_10_1002_mds_29254 crossref_primary_10_2196_39954 crossref_primary_10_1002_mds_30162 crossref_primary_10_1186_s40035_020_00187_1 crossref_primary_10_1002_mds_29055 crossref_primary_10_1002_mds_29052 crossref_primary_10_1097_01_NURSE_0000559914_46449_29 crossref_primary_10_1007_s12035_021_02596_3 crossref_primary_10_3389_fnagi_2022_831884 crossref_primary_10_1007_s40141_023_00393_8 crossref_primary_10_7759_cureus_75647 crossref_primary_10_3233_JPD_191752 crossref_primary_10_1007_s00210_018_1549_6 crossref_primary_10_1136_bmjno_2023_000484 crossref_primary_10_3389_fnagi_2021_695108 crossref_primary_10_1016_j_heliyon_2023_e16415 crossref_primary_10_1080_07391102_2021_2013320 crossref_primary_10_3389_fphar_2019_01233 crossref_primary_10_1093_ageing_afaa142 crossref_primary_10_3389_fnins_2025_1576773 crossref_primary_10_1016_j_clineuro_2024_108390 crossref_primary_10_3389_fpsyt_2023_1298359 crossref_primary_10_1016_j_mcna_2018_10_014 crossref_primary_10_1136_bmjno_2023_000469 crossref_primary_10_1002_mds_30179 crossref_primary_10_3233_JPD_212920 crossref_primary_10_3390_diagnostics12010055 crossref_primary_10_1007_s40263_020_00788_4 crossref_primary_10_26599_BSA_2024_9050026 crossref_primary_10_3233_JPD_212929 crossref_primary_10_1016_j_ejpb_2019_05_013 crossref_primary_10_3389_fncel_2018_00283 crossref_primary_10_1016_S1474_4422_19_30195_4 crossref_primary_10_1111_cns_70541 crossref_primary_10_1097_WNF_0000000000000540 crossref_primary_10_1007_s12035_023_03358_z crossref_primary_10_1186_s13024_023_00675_8 crossref_primary_10_1155_2018_6014896 crossref_primary_10_1007_s11910_020_01062_2 crossref_primary_10_1007_s10072_022_06420_1 crossref_primary_10_1007_s10072_021_05120_6 crossref_primary_10_3233_JPD_212833 crossref_primary_10_1016_j_parkreldis_2025_107779 crossref_primary_10_1371_journal_pone_0293516 crossref_primary_10_33590_emj_10314895 crossref_primary_10_1007_s40266_019_00740_2 crossref_primary_10_1016_j_parkreldis_2019_03_016 crossref_primary_10_1038_s41531_024_00772_5 crossref_primary_10_1016_j_parkreldis_2021_01_020 crossref_primary_10_1038_s44286_025_00219_5 crossref_primary_10_1016_j_toxlet_2024_12_007 crossref_primary_10_1007_s40263_020_00754_0 crossref_primary_10_3390_biom11040612 crossref_primary_10_1007_s40263_021_00862_5 crossref_primary_10_1016_j_autneu_2025_103286 crossref_primary_10_1016_j_ejphar_2022_175090 crossref_primary_10_1016_j_neulet_2020_135164 crossref_primary_10_1177_1756286420911296 crossref_primary_10_1016_S1474_4422_24_00052_8 crossref_primary_10_1177_20592043231197792 crossref_primary_10_1007_s40265_020_01307_x crossref_primary_10_1111_cns_14874 crossref_primary_10_3389_fneur_2023_1149615 crossref_primary_10_1016_j_neures_2021_12_004 crossref_primary_10_1186_s12938_023_01175_y crossref_primary_10_1007_s40263_020_00778_6 crossref_primary_10_1007_s00701_022_05302_x crossref_primary_10_3233_JPD_230354 crossref_primary_10_1002_ptr_8156 crossref_primary_10_1007_s12640_025_00742_6 crossref_primary_10_1016_j_neuropharm_2022_109027 crossref_primary_10_1007_s40120_022_00435_8 crossref_primary_10_1007_s40265_022_01747_7 crossref_primary_10_1186_s12929_021_00775_x crossref_primary_10_1080_15548627_2025_2483886 crossref_primary_10_3233_JPD_212823 crossref_primary_10_1136_bmjno_2023_000573 crossref_primary_10_1155_2019_9237181 crossref_primary_10_1007_s00701_023_05843_9 crossref_primary_10_1016_j_parkreldis_2020_09_034 crossref_primary_10_1111_cns_13713 crossref_primary_10_1177_17562864251329099 crossref_primary_10_3390_molecules24071350 crossref_primary_10_3390_md17060315 crossref_primary_10_1016_j_heliyon_2023_e21125 crossref_primary_10_1111_bcp_13651 crossref_primary_10_1007_s11011_021_00795_4 crossref_primary_10_24875_RIC_24000076 crossref_primary_10_1007_s11055_019_00822_z crossref_primary_10_1016_j_parkreldis_2023_105856 crossref_primary_10_1080_09638288_2021_1966522 crossref_primary_10_1016_S1474_4422_18_30239_4 crossref_primary_10_1016_j_ejphar_2021_174460 crossref_primary_10_1016_j_biomaterials_2019_119704 crossref_primary_10_2217_cer_2022_0031 crossref_primary_10_1016_j_arr_2024_102651 crossref_primary_10_3389_fphar_2020_00194 crossref_primary_10_1016_j_bioorg_2020_104616 crossref_primary_10_1016_j_ejphar_2018_07_043 crossref_primary_10_1155_2021_9952743 crossref_primary_10_1111_jcmm_14674 crossref_primary_10_3233_JPD_230213 crossref_primary_10_1080_14656566_2020_1805432 crossref_primary_10_1038_s41582_019_0294_x crossref_primary_10_4103_mjdrdypu_mjdrdypu_458_24 crossref_primary_10_1186_s40360_025_00886_3 crossref_primary_10_1007_s40265_020_01310_2 crossref_primary_10_3233_JPD_202096 crossref_primary_10_1016_j_neurom_2025_04_011 crossref_primary_10_3233_JPD_240011 crossref_primary_10_1159_000533793 crossref_primary_10_1007_s10143_025_03206_9 crossref_primary_10_1007_s00415_019_09486_8 crossref_primary_10_2147_DNND_S256722 crossref_primary_10_1016_j_media_2025_103727 crossref_primary_10_3390_antiox12051134 crossref_primary_10_1155_2024_5522824 crossref_primary_10_3233_JAD_200893 crossref_primary_10_3390_biom9080388 crossref_primary_10_1177_02692155231210969 crossref_primary_10_1155_2020_9131474 crossref_primary_10_61873_IBTM5678 crossref_primary_10_3390_jcm14082598 crossref_primary_10_1097_CM9_0000000000001301 crossref_primary_10_3389_fneur_2021_754016 crossref_primary_10_2174_0115734072322707240902074426 crossref_primary_10_1007_s40265_019_01201_1 crossref_primary_10_3390_s21237876 crossref_primary_10_3233_JPD_240102 crossref_primary_10_1002_mdc3_14161 crossref_primary_10_1016_j_clinph_2023_11_001 crossref_primary_10_1177_15459683211011238 crossref_primary_10_1097_MD_0000000000029931 crossref_primary_10_1007_s00210_022_02223_5 crossref_primary_10_1007_s00210_024_03215_3 crossref_primary_10_1016_j_jcomdis_2020_106031 crossref_primary_10_1038_s41531_025_01047_3 crossref_primary_10_1111_ggi_14362 crossref_primary_10_1016_j_bcp_2025_117303 crossref_primary_10_1134_S0022093025030111 crossref_primary_10_1177_1877718X251315645 crossref_primary_10_1093_neuros_nyaa228 crossref_primary_10_1177_16094069251335453 crossref_primary_10_1007_s00210_021_02162_7 crossref_primary_10_1016_j_parkreldis_2023_105885 crossref_primary_10_1080_17512433_2024_2359955 crossref_primary_10_3390_nu15122775 crossref_primary_10_1097_MD_0000000000023389 crossref_primary_10_2147_CIA_S388690 crossref_primary_10_1088_1674_1056_ac8cd8 crossref_primary_10_1038_s41531_022_00277_z crossref_primary_10_18863_pgy_1374234 crossref_primary_10_1212_WNL_0000000000012246 crossref_primary_10_1111_joim_13541 crossref_primary_10_1177_2040622319857617 crossref_primary_10_1186_s12984_020_00684_4 crossref_primary_10_3390_medicina56070356 crossref_primary_10_3389_fnagi_2018_00349 crossref_primary_10_3389_fnhum_2022_908049 crossref_primary_10_7326_AITC201809040 crossref_primary_10_1515_tnsci_2020_0104 crossref_primary_10_1016_j_arr_2024_102577 crossref_primary_10_1055_a_1534_0343 crossref_primary_10_1007_s40265_019_01104_1 crossref_primary_10_1016_j_nbd_2020_104859 crossref_primary_10_4103_0028_3886_319225 crossref_primary_10_1097_NRL_0000000000000272 crossref_primary_10_3389_fnins_2022_1084493 crossref_primary_10_1016_j_nbd_2018_11_015 crossref_primary_10_1007_s00702_025_02963_7 crossref_primary_10_3389_fdgth_2025_1590150 crossref_primary_10_3233_JND_200598 crossref_primary_10_3390_diagnostics12123132 crossref_primary_10_1371_journal_pone_0290317 crossref_primary_10_1007_s00210_024_03216_2 crossref_primary_10_1007_s00228_020_03081_x crossref_primary_10_1016_S1474_4422_24_00116_9 crossref_primary_10_1001_jamaneurol_2025_2781 crossref_primary_10_1016_j_banm_2019_11_012 crossref_primary_10_1016_j_jrras_2025_101632 crossref_primary_10_1016_j_ncl_2019_12_002 crossref_primary_10_1097_MS9_0000000000003096 crossref_primary_10_3233_JPD_213057 crossref_primary_10_1080_14737175_2019_1592677 crossref_primary_10_1016_j_parkreldis_2023_105820 crossref_primary_10_1016_j_neurol_2020_02_009 crossref_primary_10_1016_j_jns_2020_117086 crossref_primary_10_1590_1980_5764_dn_2024_0254 crossref_primary_10_1016_j_neurobiolaging_2020_08_015 crossref_primary_10_1080_09638288_2024_2310754 crossref_primary_10_1109_JSEN_2021_3121430 crossref_primary_10_2217_nmt_2021_0006 crossref_primary_10_7759_cureus_28760 crossref_primary_10_1002_jcp_31250 crossref_primary_10_1002_mdc3_70132 crossref_primary_10_3233_JPD_225068 crossref_primary_10_1016_j_hsr_2023_100096 crossref_primary_10_1002_mds_27602 crossref_primary_10_3389_fneur_2019_00934 crossref_primary_10_5334_tohm_635 crossref_primary_10_1002_advs_202417664 crossref_primary_10_3233_JPD_202184 crossref_primary_10_1007_s12311_022_01411_6 crossref_primary_10_3389_fneur_2025_1563636 crossref_primary_10_1016_j_neuroscience_2021_05_026 crossref_primary_10_1016_j_parkreldis_2022_11_002 crossref_primary_10_1016_j_biopha_2025_117862 crossref_primary_10_1016_j_neuint_2024_105803 crossref_primary_10_1016_j_parkreldis_2021_03_007 crossref_primary_10_1002_mdc3_70244 crossref_primary_10_1177_09727531231198298 crossref_primary_10_1111_ejn_15867 crossref_primary_10_1186_s12877_022_03095_3 crossref_primary_10_1093_ptj_pzaa146 crossref_primary_10_3389_fpsyg_2023_1162574 crossref_primary_10_1002_nep3_42 crossref_primary_10_1007_s13760_022_02100_1 crossref_primary_10_3233_JPD_225053 crossref_primary_10_1016_j_bioorg_2023_106543 crossref_primary_10_1016_j_brainres_2024_149129 crossref_primary_10_3233_JPD_249009 crossref_primary_10_1007_s40263_025_01179_3 crossref_primary_10_1007_s12206_022_0347_8 crossref_primary_10_1007_s40266_022_00942_1 crossref_primary_10_3233_JPD_249006 crossref_primary_10_1016_j_nec_2022_11_006 crossref_primary_10_1155_2021_6382619 crossref_primary_10_3390_genes13101863 crossref_primary_10_3233_JPD_213021 crossref_primary_10_1007_s43440_022_00378_9 crossref_primary_10_1016_j_clineuro_2024_108640 crossref_primary_10_1016_j_lfs_2022_120869 crossref_primary_10_1136_bmjopen_2018_028869 crossref_primary_10_1002_mds_27626 crossref_primary_10_1212_CPJ_0000000000200326 crossref_primary_10_3390_biom9070271 crossref_primary_10_3389_fnins_2021_728083 crossref_primary_10_1016_j_jns_2020_117277 crossref_primary_10_1016_j_wneu_2023_06_079 crossref_primary_10_1007_s40120_022_00371_7 crossref_primary_10_1038_s41597_024_03909_6 crossref_primary_10_3390_ijms23073678 crossref_primary_10_1080_17512433_2020_1724535 crossref_primary_10_4103_1673_5374_301029 crossref_primary_10_1007_s00259_023_06171_x crossref_primary_10_1007_s12325_022_02097_2 crossref_primary_10_1016_j_neuroscience_2025_08_041 crossref_primary_10_1007_s00421_024_05492_5 crossref_primary_10_1016_j_nbd_2023_106278 crossref_primary_10_2147_DDDT_S240865 crossref_primary_10_3233_JPD_202135 crossref_primary_10_1007_s40263_025_01193_5 crossref_primary_10_1016_j_cnsns_2023_107142 crossref_primary_10_1186_s12883_024_03857_z crossref_primary_10_1186_s12984_025_01640_w crossref_primary_10_1186_s13063_023_07425_7 crossref_primary_10_1016_j_addr_2025_115645 crossref_primary_10_1089_g4h_2024_0116 crossref_primary_10_4103_1673_5374_360264 crossref_primary_10_1016_j_biomaterials_2025_123548 crossref_primary_10_1097_MD_0000000000040689 crossref_primary_10_1155_2021_1599477 crossref_primary_10_1038_s41598_024_59179_0 crossref_primary_10_7861_clinmed_2020_0220 crossref_primary_10_2147_DDDT_S421449 crossref_primary_10_1016_j_jns_2020_117172 crossref_primary_10_1016_S1474_4422_20_30036_3 crossref_primary_10_1007_s00228_020_02961_6 crossref_primary_10_1093_bmb_ldad035 crossref_primary_10_1177_08919887251346495 crossref_primary_10_3390_brainsci12060689 crossref_primary_10_1007_s40263_023_01048_x crossref_primary_10_1038_s41746_019_0214_x crossref_primary_10_2217_nmt_2020_0043 crossref_primary_10_1007_s40264_023_01288_2 crossref_primary_10_3390_diagnostics12051147 crossref_primary_10_1016_j_euroneuro_2018_11_1101 crossref_primary_10_3389_fnagi_2019_00139 crossref_primary_10_1016_j_parkreldis_2019_01_002 crossref_primary_10_1159_000502288 crossref_primary_10_1097_WCO_0000000000001377 crossref_primary_10_3389_fnagi_2020_00004 crossref_primary_10_1007_s13311_020_00965_9 crossref_primary_10_1002_mdc3_13593 crossref_primary_10_1007_s13311_020_00889_4 crossref_primary_10_3389_fneur_2022_950715 crossref_primary_10_3390_brainsci14050514 crossref_primary_10_1162_netn_a_00376 crossref_primary_10_1155_2024_8448584 crossref_primary_10_1002_mds_28726 crossref_primary_10_3390_nu14142781 crossref_primary_10_1007_s40263_025_01203_6 crossref_primary_10_1016_j_clineuro_2021_106774 crossref_primary_10_3988_jcn_2025_0122 crossref_primary_10_1002_mdc3_13347 crossref_primary_10_1038_s41598_021_88910_4 crossref_primary_10_1002_mdc3_13344 crossref_primary_10_3390_cells8010014 crossref_primary_10_1016_j_jns_2020_117063 crossref_primary_10_1007_s10072_020_04396_4 crossref_primary_10_3390_jcm12196121 crossref_primary_10_1212_CPJ_0000000000001059 crossref_primary_10_1002_mdc3_13228 crossref_primary_10_3389_fneur_2022_866502 crossref_primary_10_3390_diagnostics13152511 crossref_primary_10_1111_ajr_70094 crossref_primary_10_1007_s40263_020_00727_3 crossref_primary_10_3389_fnana_2025_1566835 crossref_primary_10_1002_mds_27548 crossref_primary_10_1002_mds_28516 crossref_primary_10_3390_brainsci14010109 crossref_primary_10_1111_ene_15581 crossref_primary_10_3233_JPD_223262 crossref_primary_10_1007_s00210_024_03627_1 crossref_primary_10_1016_j_neuropharm_2020_108386 crossref_primary_10_3390_neurolint12030017 crossref_primary_10_1007_s40266_018_0629_0 crossref_primary_10_1038_s41401_021_00768_4 crossref_primary_10_1016_j_parkreldis_2023_105771 crossref_primary_10_7759_cureus_88177 crossref_primary_10_1038_s41531_022_00438_0 crossref_primary_10_1186_s12912_024_01931_y crossref_primary_10_1007_s40120_022_00351_x crossref_primary_10_1002_mdc3_13690 crossref_primary_10_1080_14740338_2019_1681966 crossref_primary_10_1111_ajr_70089 crossref_primary_10_2217_nmt_2021_0057 crossref_primary_10_1007_s40261_021_01011_y crossref_primary_10_1001_jama_2019_22360 crossref_primary_10_3390_ijms22115606 crossref_primary_10_2217_nmt_2021_0055 crossref_primary_10_2217_nmt_2021_0051 crossref_primary_10_1186_s12883_021_02248_y crossref_primary_10_1002_mds_27779 crossref_primary_10_1002_mds_28745 crossref_primary_10_1212_CPJ_0000000000200534 crossref_primary_10_3390_bs9100107 crossref_primary_10_62511_vjn_41_2024_018 crossref_primary_10_1080_14740338_2023_2227096 crossref_primary_10_3233_JPD_202217 crossref_primary_10_1002_mds_27534 crossref_primary_10_1016_j_ibneur_2021_01_002 crossref_primary_10_1016_j_revmed_2020_06_019 crossref_primary_10_3233_JPD_181484 crossref_primary_10_1007_s10072_022_06298_z crossref_primary_10_1007_s11596_023_2811_9 crossref_primary_10_1111_ene_15234 crossref_primary_10_1056_NEJMra2401857 crossref_primary_10_1016_j_jocn_2023_08_016 crossref_primary_10_1080_14728214_2020_1763954 crossref_primary_10_3233_JPD_213006 crossref_primary_10_3390_ijms24043264 crossref_primary_10_3389_fnagi_2025_1505326 crossref_primary_10_3390_cells10123547 crossref_primary_10_1155_2022_9755129 crossref_primary_10_3233_JPD_202104 crossref_primary_10_3233_JPD_202224 crossref_primary_10_1136_bmjno_2025_001115 crossref_primary_10_1016_j_parkreldis_2021_06_017 crossref_primary_10_1016_j_parkreldis_2023_105431 crossref_primary_10_3389_fnins_2020_574652 crossref_primary_10_1007_s11011_024_01397_6 crossref_primary_10_1016_j_omtn_2025_102671 crossref_primary_10_3390_molecules30153154 crossref_primary_10_1007_s10072_023_06706_y crossref_primary_10_3389_fneur_2022_818559 crossref_primary_10_3389_fneur_2023_1162016 crossref_primary_10_1016_j_biopha_2022_112907 crossref_primary_10_3390_jpm11070650 crossref_primary_10_3390_sports9060072 crossref_primary_10_1016_j_neuropharm_2020_108006 crossref_primary_10_1186_s12883_022_02830_y crossref_primary_10_3390_s25051432 crossref_primary_10_1016_j_jconrel_2023_06_026 crossref_primary_10_1016_j_ejphar_2022_175429 crossref_primary_10_3389_frvir_2020_00007 crossref_primary_10_2147_JEP_S265282 crossref_primary_10_1097_WCO_0000000000001166 crossref_primary_10_1159_000511916 crossref_primary_10_1002_mds_28880 crossref_primary_10_3389_fneur_2020_557928 crossref_primary_10_1186_s13024_023_00630_7 crossref_primary_10_1016_j_ejphar_2025_178031 crossref_primary_10_3389_fneur_2020_576569 crossref_primary_10_1007_s40120_025_00764_4 crossref_primary_10_3389_fnagi_2022_1104647 crossref_primary_10_3390_ijms26136416 crossref_primary_10_1111_ene_15651 crossref_primary_10_1080_14737175_2021_1880896 crossref_primary_10_3389_fnins_2023_1330752 crossref_primary_10_3389_fneur_2022_909197 crossref_primary_10_1186_s40035_020_00208_z crossref_primary_10_1080_17582024_2025_2528557 crossref_primary_10_1016_j_parkreldis_2022_02_014 crossref_primary_10_1155_2021_8834950 crossref_primary_10_3389_fneur_2021_707723 crossref_primary_10_1016_j_phrs_2020_105220 crossref_primary_10_1177_20592043251371380 crossref_primary_10_1016_j_clinthera_2024_01_003 crossref_primary_10_1016_j_jneuroim_2024_578345 crossref_primary_10_1242_dmm_047811 crossref_primary_10_1111_ene_15667 crossref_primary_10_3389_fnagi_2022_977100 crossref_primary_10_1016_j_eswa_2024_125506 crossref_primary_10_1007_s00415_024_12614_8 crossref_primary_10_1016_j_parkreldis_2019_06_022 crossref_primary_10_1080_14740338_2022_1988926 crossref_primary_10_1002_mds_29517 crossref_primary_10_1136_bmjopen_2023_079601 crossref_primary_10_1177_1877718X251361441 crossref_primary_10_1038_s41531_024_00803_1 crossref_primary_10_1016_j_joim_2024_07_002 crossref_primary_10_3390_diseases8020012 crossref_primary_10_1038_s41582_025_01079_6 crossref_primary_10_4252_wjsc_v17_i8_107717 crossref_primary_10_1016_j_pharmr_2025_100071 crossref_primary_10_1097_RLU_0000000000003609 crossref_primary_10_1038_s41598_025_94960_9 crossref_primary_10_1155_2021_6635618 crossref_primary_10_3389_fphar_2024_1468850 crossref_primary_10_1016_j_biopha_2023_115735 crossref_primary_10_1111_ejn_16104 crossref_primary_10_1016_j_neuropharm_2022_108998 crossref_primary_10_1136_jnnp_2023_332921 crossref_primary_10_1155_2018_8507018 crossref_primary_10_3390_ctn5020018 crossref_primary_10_1016_j_xphs_2022_02_005 crossref_primary_10_20900_agmr20250006 crossref_primary_10_1016_j_ejphar_2023_175773 crossref_primary_10_1080_14737175_2021_1851198 crossref_primary_10_3389_fneur_2022_932199 crossref_primary_10_4103_NRR_NRR_D_23_00595 crossref_primary_10_1002_mds_28332 crossref_primary_10_1016_j_bcp_2018_07_028 crossref_primary_10_3389_fneur_2019_01027 crossref_primary_10_1080_03007995_2023_2234728 crossref_primary_10_1186_s13063_018_2958_z crossref_primary_10_1155_2019_6530838 crossref_primary_10_3389_fphar_2022_805388 crossref_primary_10_1007_s10072_023_07001_6 crossref_primary_10_3389_fphar_2022_858139 crossref_primary_10_1002_agt2_403 crossref_primary_10_1155_2021_8548380 crossref_primary_10_1016_j_parkreldis_2022_02_021 crossref_primary_10_1080_23279095_2024_2423836 crossref_primary_10_1111_ene_15569 crossref_primary_10_1080_14737175_2021_1968298 crossref_primary_10_1111_ene_16535 crossref_primary_10_1016_j_neuropharm_2019_107725 crossref_primary_10_1038_s41531_024_00782_3 crossref_primary_10_1111_ejn_14173 crossref_primary_10_1016_j_neurol_2024_11_004 crossref_primary_10_3389_fneur_2023_1183823 crossref_primary_10_1002_mds_27475 crossref_primary_10_1002_mds_28322 crossref_primary_10_1002_mds_29410 crossref_primary_10_1016_j_parkreldis_2021_07_023 crossref_primary_10_1080_14737175_2020_1770598 crossref_primary_10_1002_mds_29899 crossref_primary_10_12968_bjon_2023_32_20_996 crossref_primary_10_1093_ageing_afad186 crossref_primary_10_1007_s13346_023_01449_x crossref_primary_10_1007_s00775_021_01915_2 crossref_primary_10_1080_14728214_2025_2517582 crossref_primary_10_1038_s41531_021_00194_7 crossref_primary_10_1016_j_ijpharm_2023_123218 crossref_primary_10_3390_jpm12081224 crossref_primary_10_1016_j_neuroscience_2022_03_036 crossref_primary_10_1212_CON_0000000000001152 crossref_primary_10_1080_09638288_2022_2122598 crossref_primary_10_1007_s40266_018_0599_2 crossref_primary_10_1002_mds_29200 crossref_primary_10_1007_s40120_021_00314_8 crossref_primary_10_1177_1877718X251352416 crossref_primary_10_1186_s13063_024_08092_y crossref_primary_10_3390_ijms24021685 crossref_primary_10_1002_ana_26638 crossref_primary_10_1007_s00221_024_06815_w crossref_primary_10_1007_s10072_023_07254_1 crossref_primary_10_1007_s40263_021_00888_9 crossref_primary_10_2147_DDDT_S302673 crossref_primary_10_1117_1_NPh_12_2_025008 crossref_primary_10_1007_s40120_023_00486_5 crossref_primary_10_1177_1877718X251323916 crossref_primary_10_3171_2020_6_JNS192157 crossref_primary_10_1371_journal_pone_0282348 crossref_primary_10_17116_jnevro202512508159 crossref_primary_10_1080_17434440_2025_2499153 crossref_primary_10_1002_mdc3_13962 crossref_primary_10_1007_s00702_025_02990_4 crossref_primary_10_1080_14656566_2023_2298345 crossref_primary_10_1136_jnnp_2019_322338 crossref_primary_10_1111_cns_70384 crossref_primary_10_1038_s41531_024_00716_z crossref_primary_10_3389_fnagi_2020_571185 crossref_primary_10_1111_ene_15635 crossref_primary_10_1007_s40273_022_01132_y crossref_primary_10_1097_MS9_0000000000001142 crossref_primary_10_1111_ene_15993 crossref_primary_10_1111_ene_70329 crossref_primary_10_1111_ene_15994 crossref_primary_10_1155_padi_6691390 crossref_primary_10_3389_fbioe_2021_657875 crossref_primary_10_1111_ene_15992 crossref_primary_10_1002_mdc3_13937 crossref_primary_10_1016_j_parkreldis_2019_11_011 crossref_primary_10_1212_CPJ_0000000000001143 crossref_primary_10_1080_14737175_2020_1806059 crossref_primary_10_3233_JPD_202503 crossref_primary_10_31083_j_jin2306114 crossref_primary_10_2147_CIA_S410687 crossref_primary_10_1002_brb3_2053 crossref_primary_10_1177_1877718X241297715 crossref_primary_10_1007_s10072_023_07299_2 crossref_primary_10_1007_s00415_024_12713_6 crossref_primary_10_1016_j_neuropharm_2018_05_035 crossref_primary_10_3390_jcm9051455 crossref_primary_10_1080_00207454_2021_1929217 crossref_primary_10_1016_S1474_4422_18_30496_4 crossref_primary_10_1007_s12325_022_02072_x crossref_primary_10_1016_j_neurot_2025_e00699 crossref_primary_10_1007_s40267_019_00616_w crossref_primary_10_1002_jppr_1683 crossref_primary_10_1002_mds_29210 crossref_primary_10_1002_mds_28248 crossref_primary_10_1002_mdc3_13945 crossref_primary_10_1016_j_neurol_2019_11_002 crossref_primary_10_1097_MD_0000000000020758 crossref_primary_10_3389_fneur_2022_961758 |
| Cites_doi | 10.1002/mds.25537 10.1016/j.jfma.2015.07.012 10.1016/j.parkreldis.2015.03.022 10.1002/mds.25418 10.2169/internalmedicine.52.8333 10.1056/NEJMoa1107911 10.1177/0269215514536060 10.1001/jamaneurol.2014.131 10.1177/1545968314537559 10.1177/1545968312451915 10.1017/S1461145713000175 10.1185/03007995.2015.1086994 10.1016/j.parkreldis.2017.07.029 10.1136/jnnp-2013-306787 10.1007/s40520-015-0506-1 10.1002/mds.22095 10.1002/mds.23396 10.1111/ene.13034 10.1185/03007995.2015.1005835 10.1001/jamaneurol.2014.4380 10.1212/WNL.0b013e31822affb0 10.3945/ajcn.112.051664 10.1002/ana.21315 10.1097/NPT.0000000000000101 10.1016/j.parkreldis.2014.09.022 10.1016/j.parkreldis.2012.05.010 10.1002/mds.23355 10.1212/WNL.49.3.665 10.1016/S1474-4422(12)70106-0 10.1002/mds.25321 10.1002/mds.25877 10.1007/s00702-010-0472-x 10.1111/j.1468-1331.2011.03512.x 10.1249/MSS.0000000000000945 10.1016/j.parkreldis.2015.11.004 10.1212/01.wnl.0000201252.57661.e1 10.1016/S1474-4422(15)00389-0 10.1002/mds.26528 10.1016/j.parkreldis.2014.03.019 10.1212/01.wnl.0000238518.34389.12 10.1038/nrneurol.2016.196 10.1016/S1474-4422(13)70117-0 10.1001/jamaneurol.2013.646 10.1002/mds.26256 10.1016/j.apmr.2015.10.095 10.1016/S0304-3940(03)00185-X 10.1212/WNL.0000000000000644 10.1016/j.ctim.2015.01.015 10.2522/ptj.20100423 10.1212/WNL.0000000000000050 10.1136/jnnp-2012-303182 10.1016/j.parkreldis.2015.07.020 10.1016/S1836-9553(11)70004-2 10.1212/WNL.0000000000002401 10.1136/bmjopen-2015-008756 10.1177/0269215513507462 10.5114/ninp.2013.35774 10.1371/journal.pone.0158235 10.1056/NEJMoa0907083 10.1016/j.parkreldis.2013.06.007 10.1097/NPT.0000000000000086 10.1097/WNF.0000000000000073 10.1002/mds.25831 10.1212/WNL.0000000000001155 10.1016/j.apmr.2016.11.003 10.1111/ene.12375 10.1186/s12883-016-0610-7 10.1016/j.parkreldis.2013.07.009 10.1002/mds.23107 10.1177/1545968314542981 10.1177/1545968311416990 10.1016/j.parkreldis.2014.08.004 10.1212/WNL.0b013e31825dcdc1 10.1002/mds.23829 10.2340/16501977-1056 10.1016/j.parkreldis.2013.08.017 10.1016/j.physio.2012.06.004 10.1016/j.parkreldis.2014.10.005 10.1016/j.ctim.2016.01.007 10.1016/j.parkreldis.2017.07.022 10.1016/S0140-6736(14)60683-8 10.1177/0269881114550355 10.1177/1545968311421614 10.1016/S1474-4422(11)70308-8 10.1016/j.parkreldis.2012.04.030 10.1038/nrdp.2017.13 10.1177/0269215511432652 10.1001/jama.2015.120 10.1001/jamaneurol.2015.4452 10.1016/j.parkreldis.2009.06.008 10.1212/WNL.0b013e3182143537 10.1002/mds.26286 10.1001/jamaneurol.2016.4467 10.1249/MSS.0000000000000144 10.1002/mds.25751 10.1016/j.clinph.2016.10.087 10.1017/S031716710001516X 10.1016/j.ctim.2015.01.010 10.1016/S0140-6736(16)31325-3 10.1016/j.baga.2012.05.009 10.1136/jnnp-2016-314508 10.1016/B978-0-12-801022-8.00003-9 10.2147/CIA.S68779 10.1001/archneur.64.7.nct60005 10.1016/j.apmr.2015.08.409 10.1016/j.parkreldis.2013.10.003 10.1097/WNF.0b013e31825f77b9 10.1177/0269215515570377 10.4103/0972-2327.104334 10.1097/WNF.0b013e3181342f32 10.1212/WNL.0b013e3181f6128c 10.1212/01.WNL.0000081227.84197.0B 10.1016/j.jsams.2015.01.005 10.1016/j.gaitpost.2013.02.005 10.1177/0269215514544041 10.1007/s10072-015-2433-5 10.1097/WCO.0000000000000219 10.1002/mds.23441 10.1111/ene.12666 10.1177/0269215515588836 10.1002/mds.25961 10.1002/mds.22890 10.2147/CIA.S131903 10.1016/S1474-4422(13)70293-X 10.1002/mds.23954 10.1007/s00702-013-1114-x 10.2340/16501977-2134 10.1016/S1474-4422(13)70025-5 10.1002/mds.20464 10.1177/0269215516664122 10.1016/j.apmr.2014.01.020 10.1097/WNF.0b013e318241520b 10.1097/PHM.0000000000000351 10.1002/mds.22168 10.1371/journal.pone.0015298 10.1097/PHM.0000000000000249 10.1002/mds.10370 10.2522/ptj.20110472 10.1002/ana.22060 10.1212/WNL.0b013e31822affdb 10.1001/jamaneurol.2016.4703 10.1212/01.wnl.0000313834.22171.17 10.1186/1471-2318-13-54 10.2217/nmt-2016-0005 10.1111/j.1468-1331.2012.03866.x 10.1038/srep33242 10.1016/j.parkreldis.2015.11.028 10.1016/S1474-4422(15)00336-1 10.1016/j.parkreldis.2011.09.023 10.3109/00207454.2014.991924 10.1056/NEJMoa1205158 10.1016/S1474-4422(12)70264-8 10.1016/j.gaitpost.2012.10.027 10.1016/j.parkreldis.2012.10.004 10.1002/mds.25380 10.1002/mds.26724 10.1016/j.apmr.2012.07.028 10.1002/ana.410420221 10.1016/S1474-4422(14)70055-9 10.1002/mds.22782 10.1177/0269215515570381 10.1097/NPT.0000000000000111 10.1016/S0140-6736(05)71083-7 |
| ContentType | Journal Article |
| Copyright | 2018 International Parkinson and Movement Disorder Society 2018 International Parkinson and Movement Disorder Society. |
| Copyright_xml | – notice: 2018 International Parkinson and Movement Disorder Society – notice: 2018 International Parkinson and Movement Disorder Society. |
| CorporateAuthor | on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee Movement Disorder Society Evidence-Based Medicine Committee |
| CorporateAuthor_xml | – name: on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee – name: Movement Disorder Society Evidence-Based Medicine Committee |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/mds.27372 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Physical Therapy |
| EISSN | 1531-8257 |
| EndPage | 1266 |
| ExternalDocumentID | 29570866 10_1002_mds_27372 MDS27372 |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: International Parkinson and Movement Disorder Society |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ZGI ZZTAW ~IA ~WT AAYXX CITATION O8X AAHHS ACCFJ AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM YCJ 7X8 |
| ID | FETCH-LOGICAL-c3912-ae5a69eae7a012c1b4b62055a66b13a1f245e79f5184102077f8d48e4560ef993 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 578 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000448866400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0885-3185 1531-8257 |
| IngestDate | Wed Oct 01 14:24:08 EDT 2025 Thu Apr 03 07:07:51 EDT 2025 Tue Nov 18 22:35:10 EST 2025 Sat Nov 29 07:06:39 EST 2025 Sun Sep 21 06:19:03 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Parkinson's disease monoamine oxidase inhibitors speech therapy catechol-O-methyl transferase inhibitors exercise amantadine dopamine agonists deep brain stimulation randomized controlled trial complementary therapies levodopa clozapine physical therapy neurosurgery anticholinergics evidence-based medicine occupational therapy |
| Language | English |
| License | 2018 International Parkinson and Movement Disorder Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3912-ae5a69eae7a012c1b4b62055a66b13a1f245e79f5184102077f8d48e4560ef993 |
| Notes | Nothing to report. Relevant conflicts of interests/financial disclosures ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 29570866 |
| PQID | 2018027494 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | proquest_miscellaneous_2018027494 pubmed_primary_29570866 crossref_citationtrail_10_1002_mds_27372 crossref_primary_10_1002_mds_27372 wiley_primary_10_1002_mds_27372_MDS27372 |
| PublicationCentury | 2000 |
| PublicationDate | August 2018 |
| PublicationDateYYYYMMDD | 2018-08-01 |
| PublicationDate_xml | – month: 08 year: 2018 text: August 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Movement disorders |
| PublicationTitleAlternate | Mov Disord |
| PublicationYear | 2018 |
| References | 2002; 17 2010; 16 2012; 366 2015; 72 2017; 88 2013; 368 2016; 388 2016; 31 2016; 30 2013; 70 1997; 49 2011; 57 2012; 18 2014; 29 2014; 28 2012; 15 2008; 31 2012; 11 2016; 37 2012; 98 2014; 21 2014; 20 2018; 46 2017; 74 2010; 25 2013; 2013 2015; 84 2010; 117 2013; 52 2008; 23 2016; 40 2014; 13 2012; 27 2012; 26 2007; 64 2014; 121 2014; 95 2010; 5 2016; 48 2016; 19 2013; 84 1997 2016; 97 2011; 77 2013; 93 2011; 76 2014; 46 2012; 39 2012; 35 2016; 16 2016; 15 2016; 12 2012; 30 2016; 11 2017; 53 2016; 6 2016; 7 2005; 365 2016; 28 2014; 384 2012; 44 2014; 34 2016; 25 2003; 341 2016; 23 2016; 22 2002; 59 2015; 39 2015; 38 2013; 28 2017; 3 2013; 27 2015; 31 2015; 30 2013; 20 2005; 20 2016; 73 2003; 18 2008; 70 2011; 18 2013; 19 2017; 31 2013; 16 2010; 68 2006; 67 2013; 13 2013; 12 2006; 66 2013; 94 2013; 97 2016; 86 2011; 26 2016; 115 2008; 63 2014; 6 2017; 128 2014; 119 2010; 75 2013; 47 2012 2015; 94 2015; 96 2015; 10 2008 2016; 52 2010; 362 2016; 126 2014; 85 2012; 79 2014; 83 2014; 82 2015; 23 2012; 92 2012; 2 2015; 28 2012; 3 2015; 29 2013; 38 2015; 313 2013; 32 2017; 98 2015; 22 2017; 13 2017; 12 2015; 21 2017 2015 2003; 61 2014; 71 e_1_2_8_26_1 Combs SA (e_1_2_8_52_1) 2013; 32 e_1_2_8_132_1 e_1_2_8_155_1 e_1_2_8_5_1 e_1_2_8_151_1 e_1_2_8_9_1 e_1_2_8_117_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 e_1_2_8_87_1 e_1_2_8_113_1 e_1_2_8_136_1 e_1_2_8_159_1 e_1_2_8_174_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_83_1 Mehrholz J (e_1_2_8_164_1) 2015 e_1_2_8_19_1 e_1_2_8_109_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_57_1 e_1_2_8_120_1 e_1_2_8_143_1 e_1_2_8_166_1 e_1_2_8_91_1 e_1_2_8_95_1 e_1_2_8_162_1 e_1_2_8_99_1 King LA (e_1_2_8_181_1) 2013; 2013 e_1_2_8_105_1 e_1_2_8_128_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_101_1 e_1_2_8_124_1 e_1_2_8_147_1 e_1_2_8_185_1 e_1_2_8_30_1 e_1_2_8_72_1 e_1_2_8_29_1 Goetz C (e_1_2_8_2_1) 2002; 17 Tomlinson CL (e_1_2_8_161_1) 2012 e_1_2_8_25_1 e_1_2_8_48_1 e_1_2_8_133_1 e_1_2_8_179_1 e_1_2_8_110_1 e_1_2_8_152_1 e_1_2_8_6_1 e_1_2_8_21_1 e_1_2_8_67_1 e_1_2_8_171_1 e_1_2_8_44_1 e_1_2_8_86_1 e_1_2_8_118_1 e_1_2_8_63_1 e_1_2_8_137_1 e_1_2_8_175_1 e_1_2_8_40_1 e_1_2_8_82_1 e_1_2_8_114_1 e_1_2_8_18_1 Elsner B (e_1_2_8_170_1) 2016; 7 Poliakoff E (e_1_2_8_68_1) 2013; 32 e_1_2_8_14_1 e_1_2_8_37_1 Harro CC (e_1_2_8_55_1) 2014; 34 e_1_2_8_79_1 Auff E (e_1_2_8_4_1) 2012; 3 Morrone M (e_1_2_8_76_1) 2016; 52 e_1_2_8_94_1 e_1_2_8_144_1 e_1_2_8_90_1 e_1_2_8_121_1 e_1_2_8_163_1 e_1_2_8_98_1 e_1_2_8_140_1 e_1_2_8_10_1 e_1_2_8_56_1 e_1_2_8_106_1 e_1_2_8_182_1 e_1_2_8_33_1 e_1_2_8_75_1 e_1_2_8_129_1 e_1_2_8_102_1 e_1_2_8_148_1 e_1_2_8_186_1 e_1_2_8_71_1 e_1_2_8_125_1 e_1_2_8_28_1 Dixon RA (e_1_2_8_12_1) 1997 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_3_1 e_1_2_8_81_1 e_1_2_8_111_1 e_1_2_8_130_1 e_1_2_8_153_1 e_1_2_8_7_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_89_1 Katzenschlager R (e_1_2_8_173_1) e_1_2_8_119_1 e_1_2_8_138_1 e_1_2_8_172_1 e_1_2_8_62_1 e_1_2_8_85_1 e_1_2_8_115_1 e_1_2_8_134_1 e_1_2_8_157_1 e_1_2_8_176_1 e_1_2_8_17_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 Goetz CG (e_1_2_8_178_1) 2002; 17 Santos SM (e_1_2_8_49_1) 2017; 53 e_1_2_8_70_1 e_1_2_8_122_1 e_1_2_8_141_1 e_1_2_8_97_1 e_1_2_8_160_1 e_1_2_8_32_1 e_1_2_8_78_1 e_1_2_8_107_1 e_1_2_8_149_1 e_1_2_8_183_1 Stowe RL (e_1_2_8_156_1) 2008 e_1_2_8_51_1 e_1_2_8_74_1 e_1_2_8_103_1 e_1_2_8_126_1 e_1_2_8_145_1 e_1_2_8_168_1 e_1_2_8_93_1 e_1_2_8_27_1 e_1_2_8_69_1 e_1_2_8_180_1 Dockx K (e_1_2_8_167_1) 2016; 12 e_1_2_8_80_1 e_1_2_8_154_1 e_1_2_8_131_1 e_1_2_8_150_1 e_1_2_8_8_1 Ganesan M (e_1_2_8_46_1) 2014; 6 e_1_2_8_42_1 e_1_2_8_88_1 e_1_2_8_116_1 e_1_2_8_23_1 e_1_2_8_65_1 e_1_2_8_139_1 e_1_2_8_84_1 e_1_2_8_112_1 e_1_2_8_158_1 e_1_2_8_61_1 e_1_2_8_135_1 e_1_2_8_177_1 e_1_2_8_39_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_58_1 e_1_2_8_92_1 e_1_2_8_165_1 e_1_2_8_96_1 e_1_2_8_100_1 e_1_2_8_142_1 e_1_2_8_31_1 e_1_2_8_77_1 e_1_2_8_127_1 e_1_2_8_54_1 e_1_2_8_108_1 e_1_2_8_184_1 e_1_2_8_73_1 e_1_2_8_123_1 e_1_2_8_169_1 e_1_2_8_50_1 e_1_2_8_104_1 e_1_2_8_146_1 Frazzitta G (e_1_2_8_187_1) 2012; 30 30578695 - Mov Disord. 2018 Dec;33(12):1992 |
| References_xml | – volume: 121 start-page: 357 year: 2014 end-page: 366 article-title: Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing‐off: a randomised, double‐blind trial publication-title: J Neural Transm (Vienna) – volume: 28 start-page: 1230 year: 2013 end-page: 1240 article-title: A two‐year randomized controlled trial of progressive resistance exercise for Parkinson's disease publication-title: Mov Disord – volume: 115 start-page: 734 year: 2016 end-page: 743 article-title: Home‐based virtual reality balance training and conventional balance training in Parkinson's disease: a randomized controlled trial publication-title: J Formos Med Assoc – volume: 31 start-page: 1489 year: 2016 end-page: 1496 article-title: Long‐term effects of rasagiline and the natural history of treated Parkinson's disease publication-title: Mov Disord – volume: 74 start-page: 216 year: 2017 end-page: 224 article-title: Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial publication-title: JAMA Neurol – volume: 26 start-page: 90 year: 2011 end-page: 99 article-title: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double‐blind, randomized, placebo‐controlled study (RECOVER) publication-title: Mov Disord – volume: 3 start-page: 2 year: 2012 end-page: 32 article-title: Guidelines for treatment Parkinson's disease. Part 1: Motor symptoms publication-title: Journal of Neurology – volume: 39 start-page: S1 year: 2012 end-page: S30 article-title: Canadian guidelines on Parkinson's disease publication-title: Can J Neurol Sci – volume: 27 start-page: 79 year: 2013 end-page: 86 article-title: Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial publication-title: Neurorehabil Neural Repair – volume: 29 start-page: 229 year: 2014 end-page: 237 article-title: Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations publication-title: Mov Disord – volume: 341 start-page: 201 year: 2003 end-page: 204 article-title: Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease publication-title: Neurosci Lett – volume: 39 start-page: 204 year: 2015 end-page: 212 article-title: Effects of group, individual, and home exercise in persons with Parkinson disease: a randomized clinical trial publication-title: J Neurol Phys Ther – volume: 20 start-page: 1335 year: 2014 end-page: 1340 article-title: Comparison of IPX066 with carbidopa‐levodopa plus entacapone in advanced PD patients publication-title: Parkinsonism Relat Disord – volume: 13 start-page: 141 year: 2014 end-page: 149 article-title: Continuous intrajejunal infusion of levodopa‐carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double‐blind, double‐dummy study publication-title: Lancet Neurol – volume: 96 start-page: 2103 year: 2015 end-page: 2111 article-title: Task‐ and context‐specific balance training program enhances dynamic balance and functional performance in parkinsonian nonfallers: a randomized controlled trial with six‐month follow‐up publication-title: Arch Phys Med Rehabil – volume: 25 start-page: 126 year: 2016 end-page: 131 article-title: Controlled pilot study of the effects of power yoga in Parkinson's disease publication-title: Complement Ther Med – volume: 13 start-page: 557 year: 2014 end-page: 566 article-title: Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial publication-title: Lancet Neurol – volume: 47 start-page: 256 year: 2013 end-page: 262 article-title: Influence of physiotherapy on severity of motor symptoms and quality of life in patients with Parkinson disease publication-title: Neurol Neurochir Pol – volume: 12 start-page: 619 year: 2017 end-page: 628 article-title: Systematic review on strength training in Parkinson's disease: an unsolved question publication-title: Clin Interv Aging – volume: 368 start-page: 610 year: 2013 end-page: 622 article-title: Neurostimulation for Parkinson's disease with early motor complications publication-title: N Engl J Med – volume: 18 start-page: 1373 year: 2011 end-page: 1378 article-title: Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease publication-title: Eur J Neurol – volume: 31 start-page: 1107 year: 2017 end-page: 1115 article-title: Water‐based vs. non‐water‐based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: a randomized controlled pilot study publication-title: Clin Rehabil – volume: 68 start-page: 18 year: 2010 end-page: 27 article-title: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE‐PD study publication-title: Ann Neurol – volume: 28 start-page: 1447 year: 2013 end-page: 1450 article-title: Transdermal rotigotine in early stage Parkinson's disease: a randomized, double‐blind, placebo‐controlled trial publication-title: Mov Disord – volume: 15 start-page: 154 year: 2016 end-page: 165 article-title: Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end‐of‐dose motor fluctuations: a randomised, double‐blind, controlled trial publication-title: Lancet Neurol – volume: 12 start-page: CD010760 year: 2016 article-title: Virtual reality for rehabilitation in Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 84 start-page: 552 year: 2013 end-page: 555 article-title: Memantine for axial signs in Parkinson's disease: a randomised, double‐blind, placebo‐controlled pilot study publication-title: J Neurol Neurosurg Psychiatry – volume: 23 start-page: 1255 year: 2016 end-page: 1261 article-title: A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists publication-title: Eur J Neurol – volume: 384 start-page: 1196 year: 2014 end-page: 1205 article-title: Long‐term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open‐label, pragmatic randomised trial publication-title: Lancet (London, England) – volume: 40 start-page: 24 year: 2016 end-page: 30 article-title: Highly challenging balance program reduces fall rate in Parkinson disease publication-title: J Neurol Phys Ther – volume: 26 start-page: 37 year: 2011 end-page: 44 article-title: Twice‐daily, low‐dose pramipexole in early Parkinson's disease: a randomized, placebo‐controlled trial publication-title: Mov Disord – volume: 38 start-page: 20 year: 2013 end-page: 24 article-title: Assistive devices alter gait patterns in Parkinson disease: advantages of the four‐wheeled walker publication-title: Gait Posture – volume: 70 start-page: 2233 year: 2008 end-page: 2240 article-title: A 12‐week, placebo‐controlled study (6002‐US‐006) of istradefylline in Parkinson disease publication-title: Neurology – volume: 23 start-page: 37 year: 2016 end-page: 44 article-title: Power training induced change in bradykinesia and muscle power in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 95 start-page: 1067 year: 2014 end-page: 1075 article-title: Postural rehabilitation and Kinesio taping for axial postural disorders in Parkinson's disease publication-title: Arch Phys Med Rehabil – volume: 28 start-page: 341 year: 2013 end-page: 346 article-title: Which dyskinesia scale best detects treatment response? publication-title: Mov Disord – volume: 94 start-page: 830 year: 2015 end-page: 837 article-title: Effects of treadmill training with load on gait in Parkinson disease: a randomized controlled clinical trial publication-title: Am J Phys Med Rehabil – volume: 19 start-page: 12 year: 2016 end-page: 17 article-title: Enhanced exercise therapy in Parkinson's disease: a comparative effectiveness trial publication-title: J Sci Med Sport – volume: 11 start-page: 140 year: 2012 end-page: 149 article-title: Subthalamic deep brain stimulation with a constant‐current device in Parkinson's disease: an open‐label randomised controlled trial publication-title: Lancet Neurol – volume: 46 start-page: 645 year: 2014 end-page: 655 article-title: Effects of 24 wk of treadmill training on gait performance in Parkinson's disease publication-title: Med Sci Sports Exerc – volume: 44 start-page: 944 year: 2012 end-page: 949 article-title: Repetitive step training with preparatory signals improves stability limits in patients with Parkinson's disease publication-title: J Rehabil Med – volume: 388 start-page: 1170 year: 2016 end-page: 1182 article-title: Addition of a non‐immersive virtual reality component to treadmill training to reduce fall risk in older adults (V‐TIME): a randomised controlled trial publication-title: Lancet – volume: 23 start-page: 210 year: 2015 end-page: 219 article-title: Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson's disease: a quasi‐randomized pilot trial publication-title: Complement Ther Med – volume: 365 start-page: 947 year: 2005 end-page: 954 article-title: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double‐blind, parallel‐group trial publication-title: Lancet (London, England) – volume: 28 start-page: 1210 year: 2014 end-page: 1217 article-title: Comparing the effects of hydrotherapy and land‐based therapy on balance in patients with Parkinson's disease: a randomized controlled pilot study publication-title: Clin Rehabil – volume: 73 start-page: 291 year: 2016 end-page: 299 article-title: Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease: a randomized clinical trial publication-title: JAMA Neurol – volume: 117 start-page: 1279 year: 2010 end-page: 1286 article-title: Levetiracetam for levodopa‐induced dyskinesia in Parkinson's disease: a randomized, double‐blind, placebo‐controlled trial publication-title: J Neural Transm (Vienna) – volume: 97 start-page: 345 year: 2016 end-page: 354 article-title: Comparative effect of power training and high‐speed yoga on motor function in older patients with Parkinson disease publication-title: Arch Phys Med Rehabil – start-page: CD002817 year: 2012 article-title: Physiotherapy versus placebo or no intervention in Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 19 start-page: 955 year: 2013 end-page: 960 article-title: The effect of Tai Chi exercise on gait initiation and gait performance in persons with Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 16 start-page: 16 year: 2010 end-page: 20 article-title: Istradefylline as monotherapy for Parkinson disease: results of the 6002‐US‐051 trial publication-title: Parkinsonism Relat Disord – volume: 30 start-page: 463 year: 2016 end-page: 471 article-title: Visual cues combined with treadmill training to improve gait performance in Parkinson's disease: a pilot randomized controlled trial publication-title: Clin Rehabil – volume: 94 start-page: 240 year: 2013 end-page: 249 article-title: Community‐based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson's disease publication-title: Arch Phys Med Rehabil – volume: 30 start-page: 295 year: 2012 end-page: 301 article-title: Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments publication-title: NeuroRehabilitation – volume: 29 start-page: 339 year: 2015 end-page: 347 article-title: Robot‐assisted gait training is not superior to balance training for improving postural instability in patients with mild to moderate Parkinson's disease: a single‐blind randomized controlled trial publication-title: Clin Rehabil – volume: 23 start-page: 175 year: 2015 end-page: 184 article-title: Tango for treatment of motor and non‐motor manifestations in Parkinson's disease: a randomized control study publication-title: Complement Ther Med – volume: 5 start-page: e15298 year: 2010 article-title: Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial publication-title: PloS ONE – volume: 49 start-page: 665 year: 1997 end-page: 671 article-title: Tolcapone in stable Parkinson's disease: efficacy and safety of long‐term treatment. The Tolcapone Stable Study Group publication-title: Neurology – volume: 67 start-page: 1262 year: 2006 end-page: 1264 article-title: Creatine supplementation in Parkinson disease: a placebo‐controlled randomized pilot trial publication-title: Neurology – volume: 38 start-page: 590 year: 2013 end-page: 595 article-title: The effects of treadmill or overground walking training program on gait in Parkinson's disease publication-title: Gait Posture – volume: 366 start-page: 511 year: 2012 end-page: 519 article-title: Tai chi and postural stability in patients with Parkinson's disease publication-title: N Engl J Med – volume: 52 start-page: 325 year: 2013 end-page: 332 article-title: Evaluation of the efficacy of pramipexole for treating levodopa‐induced dyskinesia in patients with Parkinson's disease publication-title: Internal medicine (Tokyo, Japan) – volume: 20 start-page: 106 year: 2014 end-page: 111 article-title: Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design publication-title: Parkinsonism Relat Disord – volume: 63 start-page: 295 year: 2008 end-page: 302 article-title: Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: a double‐blind, randomized, multicenter clinical trial (6002‐US‐005) publication-title: Ann Neurol – volume: 79 start-page: 55 year: 2012 end-page: 65 article-title: Randomized trial of deep brain stimulation for Parkinson disease: thirty‐six‐month outcomes publication-title: Neurology – volume: 71 start-page: 543 year: 2014 end-page: 552 article-title: A randomized clinical trial of high‐dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit publication-title: JAMA Neurol – volume: 20 start-page: 1388 year: 2014 end-page: 1393 article-title: Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double‐blind study publication-title: Parkinsonism Relat Disord – volume: 18 start-page: 178 year: 2012 end-page: 184 article-title: Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW‐6002‐US‐018 study publication-title: Parkinsonism Relat Disord – volume: 26 start-page: 264 year: 2011 end-page: 270 article-title: Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease publication-title: Mov Disord – volume: 30 start-page: 53 year: 2016 end-page: 63 article-title: Does attentional focus during balance training in people with Parkinson's disease affect outcome? A randomised controlled clinical trial publication-title: Clin Rehabil – volume: 94 start-page: 921 year: 2015 end-page: 929 article-title: Effects of tai chi and multimodal exercise training on movement and balance function in mild to moderate idiopathic Parkinson disease publication-title: Am J Phys Med Rehabil – volume: 77 start-page: 767 year: 2011 end-page: 774 article-title: Extended‐release pramipexole in advanced Parkinson disease: a randomized controlled trial publication-title: Neurology – volume: 26 start-page: S2 issue: suppl 3 year: 2011 end-page: S41 article-title: The Movement Disorder Society Evidence‐Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease publication-title: Mov Disord – volume: 11 start-page: e0158235 year: 2016 article-title: Bee venom for the treatment of Parkinson disease—a randomized controlled clinical trial publication-title: PloS ONE – volume: 2013 start-page: 572134 year: 2013 article-title: Exploring outcome measures for exercise intervention in people with Parkinson's disease publication-title: Parkinsons Dis – volume: 12 start-page: 747 year: 2013 end-page: 755 article-title: Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed‐start trial publication-title: Lancet Neurol – volume: 12 start-page: 346 year: 2013 end-page: 356 article-title: Extended‐release carbidopa‐levodopa (IPX066) compared with immediate‐release carbidopa‐levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double‐blind trial publication-title: Lancet Neurol – volume: 72 start-page: 432 year: 2015 end-page: 440 article-title: Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta‐analysis publication-title: JAMA Neurol – volume: 53 start-page: 173 year: 2017 end-page: 183 article-title: Balance versus resistance training on postural control in patients with Parkinson's disease: a randomized controlled trial publication-title: Eur J Phys Rehabil Med – volume: 7 start-page: CD010916 year: 2016 article-title: Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 93 start-page: 492 year: 2013 end-page: 503 article-title: Effect of externally cued training on dynamic stability control during the sit‐to‐stand task in people with Parkinson disease publication-title: Phys Ther – volume: 313 start-page: 584 year: 2015 end-page: 593 article-title: Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial publication-title: JAMA – volume: 39 start-page: 85 year: 2015 end-page: 92 article-title: Exercise and medication effects on persons with Parkinson disease across the domains of disability: a randomized clinical trial publication-title: J Neurol Phys Ther – volume: 18 start-page: 382 year: 2003 end-page: 388 article-title: 0.2‐Hz repetitive transcranial magnetic stimulation has no add‐on effects as compared to a realistic sham stimulation in Parkinson's disease publication-title: Mov Disord – volume: 362 start-page: 2077 year: 2010 end-page: 2091 article-title: Pallidal versus subthalamic deep‐brain stimulation for Parkinson's disease publication-title: N Engl J Med – volume: 31 start-page: 141 year: 2008 end-page: 150 article-title: A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18‐month results publication-title: Clin Neuropharmacol – volume: 20 start-page: 731 year: 2014 end-page: 737 article-title: Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 48 start-page: 1678 year: 2016 end-page: 1687 article-title: Resistance training with instability for patients with Parkinson's disease publication-title: Med Sci Sports Exerc – volume: 38 start-page: 41 year: 2015 end-page: 46 article-title: A long‐term study of istradefylline safety and efficacy in patients with Parkinson disease publication-title: Clin Neuropharmacol – volume: 52 start-page: 799 year: 2016 end-page: 809 article-title: Perceptive rehabilitation and trunk posture alignment in patients with Parkinson disease: a single blind randomized controlled trial publication-title: Eur J Phys Rehabil Med – volume: 30 start-page: 1343 year: 2015 end-page: 1350 article-title: Zonisamide improves wearing‐off in Parkinson's disease: a randomized, double‐blind study publication-title: Mov Disord – volume: 37 start-page: 515 year: 2016 end-page: 522 article-title: Effects of global postural reeducation on gait kinematics in parkinsonian patients: a pilot randomized three‐dimensional motion analysis study publication-title: Neurol Sci – volume: 92 start-page: 1395 year: 2012 end-page: 1410 article-title: Exercise for people in early‐ or mid‐stage Parkinson disease: a 16‐month randomized controlled trial publication-title: Phys Ther – volume: 34 start-page: 557 year: 2014 end-page: 572 article-title: The effects of speed‐dependent treadmill training and rhythmic auditory‐cued overground walking on gait function and fall risk in individuals with idiopathic Parkinson's disease: a randomized controlled trial publication-title: NeuroRehabilitation – volume: 13 start-page: 54 year: 2013 article-title: A comparison of Irish set dancing and exercises for people with Parkinson's disease: a phase II feasibility study publication-title: BMC Geriatr – volume: 82 start-page: 300 year: 2014 end-page: 307 article-title: Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial publication-title: Neurology – volume: 128 start-page: 56 year: 2017 end-page: 92 article-title: Evidence‐based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS) publication-title: Clin Neurophysiol – volume: 83 start-page: 413 year: 2014 end-page: 425 article-title: Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting publication-title: Neurology – volume: 46 start-page: S47 issue: suppl 1 year: 2018 end-page: S52 article-title: Historical perspective: the pros and cons of conventional outcome measures in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 26 start-page: 132 year: 2012 end-page: 143 article-title: Randomized controlled trial of community‐based dancing to modify disease progression in Parkinson disease publication-title: Neurorehabil Neural Repair – volume: 28 start-page: 275 year: 2014 end-page: 288 article-title: Leg muscle power is enhanced by training in people with Parkinson's disease: a randomized controlled trial publication-title: Clin Rehabil – volume: 35 start-page: 174 year: 2012 end-page: 181 article-title: Efficacy and safety of extended‐ versus immediate‐release pramipexole in Japanese patients with advanced and L‐dopa‐undertreated Parkinson disease: a double‐blind, randomized trial publication-title: Clin Neuropharmacol – volume: 119 start-page: 71 year: 2014 end-page: 86 article-title: An overview of adenosine A2A receptor antagonists in Parkinson's disease publication-title: Int Rev Neurobiol – volume: 12 start-page: 37 year: 2013 end-page: 44 article-title: Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial publication-title: Lancet Neurol – volume: 98 start-page: 622 year: 2017 end-page: 630 article-title: Wearable sensor‐based biofeedback training for balance and gait in Parkinson disease: a pilot randomized controlled trial publication-title: Arch Phys Med Rehabil – volume: 19 start-page: 1022 year: 2013 end-page: 1026 article-title: The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double‐blind, randomized, placebo‐controlled study publication-title: Parkinsonism Relat Disord – volume: 2 start-page: 79 year: 2012 end-page: 85 article-title: Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: results from a 1‐year, open‐label extension of the RECOVER study publication-title: Basal Ganglia – volume: 6 start-page: e008756 year: 2016 article-title: Progressive resistance training in Parkinson's disease: a systematic review and meta‐analysis publication-title: BMJ Open – volume: 30 start-page: 11 year: 2016 end-page: 23 article-title: Effectiveness of resistance training on muscle strength and physical function in people with Parkinson's disease: a systematic review and meta‐analysis publication-title: Clin Rehabil – volume: 32 start-page: 117 year: 2013 end-page: 124 article-title: Community‐based group exercise for persons with Parkinson disease: a randomized controlled trial publication-title: NeuroRehabilitation – volume: 28 start-page: 1088 year: 2014 end-page: 1098 article-title: Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double‐blind trial publication-title: J Psychopharmacol – volume: 46 start-page: S53 issue: suppl 1 year: 2018 end-page: S56 article-title: Integration of technology‐based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases publication-title: Parkinsonism Relat Disord – volume: 16 start-page: 1529 year: 2013 end-page: 1537 article-title: Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double‐blind, parallel‐controlled, multi‐centre trial publication-title: Int J Neuropsychopharmacol – volume: 16 start-page: 90 year: 2016 article-title: Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease publication-title: BMC Neurol – volume: 26 start-page: 817 year: 2012 end-page: 826 article-title: Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial publication-title: Clin Rehabil – volume: 25 start-page: 858 year: 2010 end-page: 866 article-title: Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease publication-title: Mov Disord – volume: 97 start-page: 1004 year: 2013 end-page: 1013 article-title: Randomized, double‐blind, placebo‐controlled trial of vitamin D supplementation in Parkinson disease publication-title: Am J Clin Nutri – volume: 76 start-page: 1256 year: 2011 end-page: 1262 article-title: Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial publication-title: Neurology – volume: 28 start-page: 382 year: 2015 end-page: 386 article-title: Subtypes of Parkinson's disease: state of the field and future directions publication-title: Curr Opin Neurol – volume: 28 start-page: 1138 year: 2013 end-page: 1141 article-title: Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease publication-title: Mov Disord – volume: 35 start-page: 15 year: 2012 end-page: 20 article-title: Perampanel in Parkinson disease fluctuations: a double‐blind randomized trial with placebo and entacapone publication-title: Clin Neuropharmacol – volume: 31 start-page: 2055 year: 2015 end-page: 2058 article-title: Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial publication-title: Curr Med Res Opin – volume: 25 start-page: S141 issue: suppl 1 year: 2010 end-page: S145 article-title: Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease publication-title: Mov Disord – volume: 27 start-page: 106 year: 2012 end-page: 112 article-title: A randomized, double‐blind, placebo‐controlled trial of safinamide as add‐on therapy in early Parkinson's disease patients publication-title: Mov Disord – volume: 88 start-page: 204 year: 2017 end-page: 211 article-title: Phase II randomised controlled trial of a 6‐month self‐managed community exercise programme for people with Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 29 start-page: 1273 year: 2014 end-page: 1280 article-title: Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease publication-title: Mov Disord – volume: 86 start-page: 755 year: 2016 end-page: 761 article-title: GPi vs STN deep brain stimulation for Parkinson disease: Three‐year follow‐up publication-title: Neurology – volume: 66 start-page: 664 year: 2006 end-page: 671 article-title: A randomized, double‐blind, futility clinical trial of creatine and minocycline in early Parkinson disease publication-title: Neurology – volume: 10 start-page: 183 year: 2015 end-page: 191 article-title: Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson's disease: pilot study publication-title: Clin Interv Aging – year: 1997 – volume: 20 start-page: 142 year: 2014 end-page: 148 article-title: Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 22 start-page: 28 year: 2016 end-page: 34 article-title: Feasibility and effects of home‐based smartphone‐delivered automated feedback training for gait in people with Parkinson's disease: a pilot randomized controlled trial publication-title: Parkinsonism Relat Disord – volume: 48 start-page: 819 year: 2016 end-page: 823 article-title: Dopamine‐independent effects of combining transcranial direct current stimulation with cued gait training on cortical excitability and functional mobility in Parkinson's disease publication-title: J Rehabil Med – volume: 22 start-page: 815 year: 2015 end-page: 825 article-title: Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease publication-title: Eur J Neurol – volume: 29 start-page: 949 year: 2014 end-page: 953 article-title: The effect of deep brain stimulation randomized by site on balance in Parkinson's disease publication-title: Mov Disord – volume: 21 start-page: 736 year: 2014 end-page: 743 article-title: Long‐term safety and sustained efficacy of extended‐release pramipexole in early and advanced Parkinson's disease publication-title: Euro J Neurol – volume: 23 start-page: 2177 year: 2008 end-page: 2185 article-title: Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations publication-title: Mov Disord – start-page: CD006564 year: 2008 article-title: Dopamine agonist therapy in early Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 17 start-page: S1 issue: suppl 4 year: 2002 end-page: 166 article-title: Management of Parkinson's disease: an evidence‐based review publication-title: Mov Disord – volume: 61 start-page: 297 year: 2003 end-page: 303 article-title: Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD publication-title: Neurology – volume: 15 start-page: 249 year: 2016 end-page: 258 article-title: Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double‐blind, placebo‐controlled, phase 2 trial publication-title: Lancet Neurol – volume: 21 start-page: 615 year: 2015 end-page: 621 article-title: Multi‐dimensional balance training programme improves balance and gait performance in people with Parkinson's disease: a pragmatic randomized controlled trial with 12‐month follow‐up publication-title: Parkinsonism Relat Disord – volume: 20 start-page: 1352 year: 2014 end-page: 1358 article-title: Effects of augmented visual feedback during balance training in Parkinson's disease: a pilot randomized clinical trial publication-title: Parkinsonism Relat Disord – volume: 32 start-page: 125 year: 2013 end-page: 134 article-title: The effect of gym training on multiple outcomes in Parkinson's disease: a pilot randomised waiting‐list controlled trial publication-title: NeuroRehabilitation – volume: 126 start-page: 30 year: 2016 end-page: 38 article-title: Long‐term, open‐label, safety study of once‐daily ropinirole extended/prolonged release in early and advanced Parkinson's disease publication-title: Int J Neurosci – volume: 6 start-page: 22 year: 2014 end-page: 33 article-title: Effect of partial weight‐supported treadmill gait training on balance in patients with Parkinson disease publication-title: Physical Medicine and Rehabilitation – volume: 57 start-page: 27 year: 2011 end-page: 34 article-title: Rehabilitation with mental practice has similar effects on mobility as rehabilitation with relaxation in people with Parkinson's disease: a multicentre randomised trial publication-title: J Physiother – volume: 85 start-page: 840 year: 2014 end-page: 844 article-title: Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study publication-title: J Neurol Neurosurg Psychiatry – volume: 18 start-page: 990 year: 2012 end-page: 993 article-title: Does robotic gait training improve balance in Parkinson's disease? A randomized controlled trial publication-title: Parkinsonism Relat Disord – volume: 20 start-page: 5 year: 2013 end-page: 15 article-title: Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease publication-title: Euro J Neurol – volume: 20 start-page: 523 year: 2005 end-page: 539 article-title: Evidence‐based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 publication-title: Mov Disord – volume: 26 start-page: 144 year: 2012 end-page: 150 article-title: Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1‐year follow‐up publication-title: Neurorehabil Neural Repair – volume: 23 start-page: 1524 year: 2008 end-page: 1531 article-title: High‐frequency rTMS over the supplementary motor area for treatment of Parkinson's disease publication-title: Mov Disord – volume: 6 start-page: 249 year: 2016 end-page: 268 article-title: Nondopaminergic treatments for Parkinson's disease: current and future prospects publication-title: Neurodegener Dis Manag – volume: 75 start-page: 1263 year: 2010 end-page: 1269 article-title: Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease publication-title: Neurology – volume: 11 start-page: 589 year: 2012 end-page: 596 article-title: Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo‐controlled trial publication-title: Lancet Neurol – volume: 19 start-page: 207 year: 2013 end-page: 211 article-title: Video‐assisted swallowing therapy for patients with Parkinson's disease publication-title: Parkinsonism Relat Disord – start-page: CD007830 year: 2015 article-title: Treadmill training for patients with Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 84 start-page: 304 year: 2015 end-page: 312 article-title: Exercise for falls prevention in Parkinson disease: a randomized controlled trial publication-title: Neurology – volume: 18 start-page: 948 year: 2012 end-page: 952 article-title: Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 29 start-page: 1028 year: 2014 end-page: 1034 article-title: Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease publication-title: Mov Disord – volume: 98 start-page: 196 year: 2012 end-page: 204 article-title: Effect of Nintendo Wii‐based motor and cognitive training on activities of daily living in patients with Parkinson's disease: a randomised clinical trial publication-title: Physiotherapy – volume: 29 start-page: 103 year: 2015 end-page: 111 article-title: Technology‐assisted balance and gait training reduces falls in patients with Parkinson's disease: a randomized controlled trial with 12‐month follow‐up publication-title: Neurorehabil Neural Repair – volume: 15 start-page: 267 year: 2012 end-page: 272 article-title: Effects of augmented proprioceptive cues on the parameters of gait of individuals with Parkinson's disease publication-title: Ann Indian Acad Neurol – volume: 28 start-page: 1169 year: 2016 end-page: 1177 article-title: The effect of the rehabilitation program on balance, gait, physical performance and trunk rotation in Parkinson's disease publication-title: Aging Clin Exp Res – volume: 21 start-page: 1133 year: 2015 end-page: 1144 article-title: Collective physician perspectives on non‐oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program publication-title: Parkinsonism Relat Disord – volume: 59 start-page: 1541 year: 2002 end-page: 1550 article-title: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline publication-title: Arch Neurol – volume: 77 start-page: 759 year: 2011 end-page: 766 article-title: Extended‐release pramipexole in early Parkinson disease: a 33‐week randomized controlled trial publication-title: Neurology – volume: 64 start-page: 938 year: 2007 end-page: 944 article-title: Randomized, double‐blind, placebo‐controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease publication-title: Arch Neurol – volume: 17 start-page: S1 issue: suppl 4 year: 2002 end-page: S166 article-title: Management of Parkinson's disease: an evidence‐based review publication-title: Mov Disord – volume: 29 start-page: 123 year: 2015 end-page: 131 article-title: Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2‐year follow‐up publication-title: Neurorehabil Neural Repair – volume: 6 start-page: 33242 year: 2016 article-title: Positive effects of specific exercise and novel turning‐based treadmill training on turning performance in individuals with Parkinson's disease: a randomized controlled trial publication-title: Sci Rep – volume: 74 start-page: 197 year: 2017 end-page: 206 article-title: Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial publication-title: JAMA Neurol – volume: 13 start-page: 119 year: 2017 end-page: 126 article-title: Precision medicine for disease modification in Parkinson disease publication-title: Nat Rev Neurol – volume: 31 start-page: 530 year: 2016 end-page: 537 article-title: Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients publication-title: Mov Disord – year: 2017 – volume: 31 start-page: 723 year: 2015 end-page: 730 article-title: An open‐label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease publication-title: Curr Med Res Opin – volume: 30 start-page: 1050 year: 2015 end-page: 1058 article-title: In‐patient multidisciplinary rehabilitation for Parkinson's disease: a randomized controlled trial publication-title: Mov Disord – volume: 25 start-page: 1437 year: 2010 end-page: 1443 article-title: Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: a randomized, controlled study publication-title: Mov Disord – volume: 70 start-page: 183 year: 2013 end-page: 190 article-title: Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease publication-title: JAMA Neurol – volume: 3 start-page: 17013 year: 2017 article-title: Parkinson disease publication-title: Nat Rev Dis Primers – ident: e_1_2_8_27_1 doi: 10.1002/mds.25537 – ident: e_1_2_8_81_1 doi: 10.1016/j.jfma.2015.07.012 – ident: e_1_2_8_182_1 doi: 10.1016/j.parkreldis.2015.03.022 – ident: e_1_2_8_132_1 doi: 10.1002/mds.25418 – ident: e_1_2_8_143_1 doi: 10.2169/internalmedicine.52.8333 – ident: e_1_2_8_91_1 doi: 10.1056/NEJMoa1107911 – ident: e_1_2_8_47_1 doi: 10.1177/0269215514536060 – ident: e_1_2_8_16_1 doi: 10.1001/jamaneurol.2014.131 – ident: e_1_2_8_87_1 doi: 10.1177/1545968314537559 – ident: e_1_2_8_105_1 doi: 10.1177/1545968312451915 – ident: e_1_2_8_123_1 doi: 10.1017/S1461145713000175 – ident: e_1_2_8_135_1 doi: 10.1185/03007995.2015.1086994 – ident: e_1_2_8_150_1 doi: 10.1016/j.parkreldis.2017.07.029 – ident: e_1_2_8_154_1 doi: 10.1136/jnnp-2013-306787 – ident: e_1_2_8_69_1 doi: 10.1007/s40520-015-0506-1 – ident: e_1_2_8_129_1 doi: 10.1002/mds.22095 – ident: e_1_2_8_24_1 doi: 10.1002/mds.23396 – volume: 6 start-page: 22 year: 2014 ident: e_1_2_8_46_1 article-title: Effect of partial weight‐supported treadmill gait training on balance in patients with Parkinson disease publication-title: Physical Medicine and Rehabilitation – ident: e_1_2_8_155_1 doi: 10.1111/ene.13034 – ident: e_1_2_8_113_1 doi: 10.1185/03007995.2015.1005835 – ident: e_1_2_8_168_1 doi: 10.1001/jamaneurol.2014.4380 – ident: e_1_2_8_25_1 doi: 10.1212/WNL.0b013e31822affb0 – ident: e_1_2_8_21_1 doi: 10.3945/ajcn.112.051664 – ident: e_1_2_8_130_1 doi: 10.1002/ana.21315 – ident: e_1_2_8_48_1 doi: 10.1097/NPT.0000000000000101 – ident: e_1_2_8_82_1 doi: 10.1016/j.parkreldis.2014.09.022 – ident: e_1_2_8_83_1 doi: 10.1016/j.parkreldis.2012.05.010 – ident: e_1_2_8_147_1 doi: 10.1002/mds.23355 – start-page: CD007830 year: 2015 ident: e_1_2_8_164_1 article-title: Treadmill training for patients with Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_159_1 doi: 10.1212/WNL.49.3.665 – volume: 32 start-page: 125 year: 2013 ident: e_1_2_8_68_1 article-title: The effect of gym training on multiple outcomes in Parkinson's disease: a pilot randomised waiting‐list controlled trial publication-title: NeuroRehabilitation – ident: e_1_2_8_38_1 doi: 10.1016/S1474-4422(12)70106-0 – ident: e_1_2_8_145_1 doi: 10.1002/mds.25321 – ident: e_1_2_8_33_1 doi: 10.1002/mds.25877 – ident: e_1_2_8_148_1 doi: 10.1007/s00702-010-0472-x – ident: e_1_2_8_185_1 doi: 10.1111/j.1468-1331.2011.03512.x – ident: e_1_2_8_62_1 doi: 10.1249/MSS.0000000000000945 – ident: e_1_2_8_86_1 doi: 10.1016/j.parkreldis.2015.11.004 – volume: 34 start-page: 557 year: 2014 ident: e_1_2_8_55_1 article-title: The effects of speed‐dependent treadmill training and rhythmic auditory‐cued overground walking on gait function and fall risk in individuals with idiopathic Parkinson's disease: a randomized controlled trial publication-title: NeuroRehabilitation – ident: e_1_2_8_179_1 doi: 10.1212/01.wnl.0000201252.57661.e1 – ident: e_1_2_8_37_1 doi: 10.1016/S1474-4422(15)00389-0 – ident: e_1_2_8_175_1 doi: 10.1002/mds.26528 – ident: e_1_2_8_35_1 doi: 10.1016/j.parkreldis.2014.03.019 – ident: e_1_2_8_20_1 doi: 10.1212/01.wnl.0000238518.34389.12 – ident: e_1_2_8_152_1 doi: 10.1038/nrneurol.2016.196 – ident: e_1_2_8_13_1 doi: 10.1016/S1474-4422(13)70117-0 – ident: e_1_2_8_43_1 doi: 10.1001/jamaneurol.2013.646 – ident: e_1_2_8_9_1 – ident: e_1_2_8_42_1 doi: 10.1002/mds.26256 – ident: e_1_2_8_95_1 doi: 10.1016/j.apmr.2015.10.095 – ident: e_1_2_8_17_1 doi: 10.1016/S0304-3940(03)00185-X – ident: e_1_2_8_56_1 doi: 10.1212/WNL.0000000000000644 – ident: e_1_2_8_100_1 doi: 10.1016/j.ctim.2015.01.015 – ident: e_1_2_8_89_1 doi: 10.2522/ptj.20100423 – ident: e_1_2_8_146_1 doi: 10.1212/WNL.0000000000000050 – ident: e_1_2_8_40_1 doi: 10.1136/jnnp-2012-303182 – ident: e_1_2_8_174_1 doi: 10.1016/j.parkreldis.2015.07.020 – ident: e_1_2_8_74_1 doi: 10.1016/S1836-9553(11)70004-2 – ident: e_1_2_8_138_1 doi: 10.1212/WNL.0000000000002401 – ident: e_1_2_8_163_1 doi: 10.1136/bmjopen-2015-008756 – volume: 2013 start-page: 572134 year: 2013 ident: e_1_2_8_181_1 article-title: Exploring outcome measures for exercise intervention in people with Parkinson's disease publication-title: Parkinsons Dis – ident: e_1_2_8_57_1 doi: 10.1177/0269215513507462 – ident: e_1_2_8_67_1 doi: 10.5114/ninp.2013.35774 – ident: e_1_2_8_109_1 doi: 10.1371/journal.pone.0158235 – ident: e_1_2_8_139_1 doi: 10.1056/NEJMoa0907083 – ident: e_1_2_8_93_1 doi: 10.1016/j.parkreldis.2013.06.007 – ident: e_1_2_8_60_1 doi: 10.1097/NPT.0000000000000086 – ident: e_1_2_8_133_1 doi: 10.1097/WNF.0000000000000073 – ident: e_1_2_8_142_1 doi: 10.1002/mds.25831 – start-page: CD006564 year: 2008 ident: e_1_2_8_156_1 article-title: Dopamine agonist therapy in early Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_71_1 doi: 10.1212/WNL.0000000000001155 – ident: e_1_2_8_80_1 doi: 10.1016/j.apmr.2016.11.003 – ident: e_1_2_8_26_1 doi: 10.1111/ene.12375 – ident: e_1_2_8_28_1 doi: 10.1186/s12883-016-0610-7 – ident: e_1_2_8_112_1 doi: 10.1016/j.parkreldis.2013.07.009 – ident: e_1_2_8_186_1 doi: 10.1002/mds.23107 – ident: e_1_2_8_7_1 – ident: e_1_2_8_23_1 doi: 10.1177/1545968314542981 – volume: 52 start-page: 799 year: 2016 ident: e_1_2_8_76_1 article-title: Perceptive rehabilitation and trunk posture alignment in patients with Parkinson disease: a single blind randomized controlled trial publication-title: Eur J Phys Rehabil Med – ident: e_1_2_8_45_1 doi: 10.1177/1545968311416990 – volume: 12 start-page: CD010760 year: 2016 ident: e_1_2_8_167_1 article-title: Virtual reality for rehabilitation in Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_116_1 doi: 10.1016/j.parkreldis.2014.08.004 – ident: e_1_2_8_140_1 doi: 10.1212/WNL.0b013e31825dcdc1 – ident: e_1_2_8_10_1 doi: 10.1002/mds.23829 – ident: e_1_2_8_75_1 doi: 10.2340/16501977-1056 – ident: e_1_2_8_30_1 doi: 10.1016/j.parkreldis.2013.08.017 – ident: e_1_2_8_85_1 doi: 10.1016/j.physio.2012.06.004 – ident: e_1_2_8_111_1 doi: 10.1016/j.parkreldis.2014.10.005 – ident: e_1_2_8_177_1 – ident: e_1_2_8_94_1 doi: 10.1016/j.ctim.2016.01.007 – ident: e_1_2_8_166_1 doi: 10.1016/j.parkreldis.2017.07.022 – ident: e_1_2_8_29_1 doi: 10.1016/S0140-6736(14)60683-8 – ident: e_1_2_8_41_1 doi: 10.1177/0269881114550355 – volume: 32 start-page: 117 year: 2013 ident: e_1_2_8_52_1 article-title: Community‐based group exercise for persons with Parkinson disease: a randomized controlled trial publication-title: NeuroRehabilitation – ident: e_1_2_8_96_1 doi: 10.1177/1545968311421614 – ident: e_1_2_8_136_1 doi: 10.1016/S1474-4422(11)70308-8 – ident: e_1_2_8_108_1 doi: 10.1016/j.parkreldis.2012.04.030 – ident: e_1_2_8_153_1 doi: 10.1038/nrdp.2017.13 – volume-title: Double‐blind, randomized, placebo‐controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson's disease patients with motor fluctuations not well controlled on optimized medical treatment ident: e_1_2_8_173_1 – ident: e_1_2_8_50_1 doi: 10.1177/0269215511432652 – ident: e_1_2_8_19_1 doi: 10.1001/jama.2015.120 – ident: e_1_2_8_102_1 doi: 10.1001/jamaneurol.2015.4452 – ident: e_1_2_8_31_1 doi: 10.1016/j.parkreldis.2009.06.008 – ident: e_1_2_8_39_1 doi: 10.1212/WNL.0b013e3182143537 – ident: e_1_2_8_124_1 doi: 10.1002/mds.26286 – ident: e_1_2_8_126_1 doi: 10.1001/jamaneurol.2016.4467 – ident: e_1_2_8_54_1 doi: 10.1249/MSS.0000000000000144 – ident: e_1_2_8_125_1 doi: 10.1002/mds.25751 – ident: e_1_2_8_169_1 doi: 10.1016/j.clinph.2016.10.087 – volume: 17 start-page: S1 issue: 4 year: 2002 ident: e_1_2_8_178_1 article-title: Management of Parkinson's disease: an evidence‐based review publication-title: Mov Disord – ident: e_1_2_8_6_1 doi: 10.1017/S031716710001516X – ident: e_1_2_8_99_1 doi: 10.1016/j.ctim.2015.01.010 – ident: e_1_2_8_79_1 doi: 10.1016/S0140-6736(16)31325-3 – ident: e_1_2_8_114_1 doi: 10.1016/j.baga.2012.05.009 – ident: e_1_2_8_66_1 doi: 10.1136/jnnp-2016-314508 – ident: e_1_2_8_158_1 doi: 10.1016/B978-0-12-801022-8.00003-9 – start-page: CD002817 year: 2012 ident: e_1_2_8_161_1 article-title: Physiotherapy versus placebo or no intervention in Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_58_1 doi: 10.2147/CIA.S68779 – volume: 7 start-page: CD010916 year: 2016 ident: e_1_2_8_170_1 article-title: Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_15_1 doi: 10.1001/archneur.64.7.nct60005 – ident: e_1_2_8_73_1 doi: 10.1016/j.apmr.2015.08.409 – ident: e_1_2_8_22_1 doi: 10.1016/j.parkreldis.2013.10.003 – ident: e_1_2_8_32_1 doi: 10.1097/WNF.0b013e31825f77b9 – ident: e_1_2_8_77_1 doi: 10.1177/0269215515570377 – ident: e_1_2_8_88_1 doi: 10.4103/0972-2327.104334 – ident: e_1_2_8_180_1 doi: 10.1097/WNF.0b013e3181342f32 – volume-title: The Evidence Based Medicine Workbook : Critical Appraisal for Clinical Problem Solving year: 1997 ident: e_1_2_8_12_1 – ident: e_1_2_8_36_1 doi: 10.1212/WNL.0b013e3181f6128c – ident: e_1_2_8_128_1 doi: 10.1212/01.WNL.0000081227.84197.0B – volume: 17 start-page: S1 issue: 4 year: 2002 ident: e_1_2_8_2_1 article-title: Management of Parkinson's disease: an evidence‐based review publication-title: Mov Disord – ident: e_1_2_8_64_1 doi: 10.1016/j.jsams.2015.01.005 – ident: e_1_2_8_53_1 doi: 10.1016/j.gaitpost.2013.02.005 – ident: e_1_2_8_84_1 doi: 10.1177/0269215514544041 – ident: e_1_2_8_59_1 doi: 10.1007/s10072-015-2433-5 – ident: e_1_2_8_151_1 doi: 10.1097/WCO.0000000000000219 – ident: e_1_2_8_184_1 doi: 10.1002/mds.23441 – ident: e_1_2_8_122_1 doi: 10.1111/ene.12666 – ident: e_1_2_8_183_1 doi: 10.1177/0269215515588836 – ident: e_1_2_8_127_1 doi: 10.1002/mds.25961 – ident: e_1_2_8_157_1 doi: 10.1002/mds.22890 – ident: e_1_2_8_165_1 doi: 10.2147/CIA.S131903 – ident: e_1_2_8_117_1 doi: 10.1016/S1474-4422(13)70293-X – ident: e_1_2_8_34_1 doi: 10.1002/mds.23954 – ident: e_1_2_8_119_1 doi: 10.1007/s00702-013-1114-x – ident: e_1_2_8_107_1 doi: 10.2340/16501977-2134 – ident: e_1_2_8_115_1 doi: 10.1016/S1474-4422(13)70025-5 – volume: 30 start-page: 295 year: 2012 ident: e_1_2_8_187_1 article-title: Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments publication-title: NeuroRehabilitation – ident: e_1_2_8_3_1 doi: 10.1002/mds.20464 – ident: e_1_2_8_63_1 doi: 10.1177/0269215516664122 – ident: e_1_2_8_78_1 doi: 10.1016/j.apmr.2014.01.020 – ident: e_1_2_8_11_1 – ident: e_1_2_8_118_1 doi: 10.1097/WNF.0b013e318241520b – ident: e_1_2_8_92_1 doi: 10.1097/PHM.0000000000000351 – ident: e_1_2_8_104_1 doi: 10.1002/mds.22168 – ident: e_1_2_8_144_1 doi: 10.1371/journal.pone.0015298 – ident: e_1_2_8_61_1 doi: 10.1097/PHM.0000000000000249 – ident: e_1_2_8_106_1 doi: 10.1002/mds.10370 – ident: e_1_2_8_51_1 doi: 10.2522/ptj.20110472 – ident: e_1_2_8_160_1 doi: 10.1002/ana.22060 – ident: e_1_2_8_110_1 doi: 10.1212/WNL.0b013e31822affdb – ident: e_1_2_8_121_1 doi: 10.1001/jamaneurol.2016.4703 – ident: e_1_2_8_131_1 doi: 10.1212/01.wnl.0000313834.22171.17 – ident: e_1_2_8_98_1 doi: 10.1186/1471-2318-13-54 – ident: e_1_2_8_176_1 doi: 10.2217/nmt-2016-0005 – volume: 53 start-page: 173 year: 2017 ident: e_1_2_8_49_1 article-title: Balance versus resistance training on postural control in patients with Parkinson's disease: a randomized controlled trial publication-title: Eur J Phys Rehabil Med – ident: e_1_2_8_5_1 doi: 10.1111/j.1468-1331.2012.03866.x – ident: e_1_2_8_65_1 doi: 10.1038/srep33242 – ident: e_1_2_8_70_1 doi: 10.1016/j.parkreldis.2015.11.028 – ident: e_1_2_8_120_1 doi: 10.1016/S1474-4422(15)00336-1 – ident: e_1_2_8_134_1 doi: 10.1016/j.parkreldis.2011.09.023 – ident: e_1_2_8_171_1 doi: 10.3109/00207454.2014.991924 – ident: e_1_2_8_141_1 doi: 10.1056/NEJMoa1205158 – ident: e_1_2_8_137_1 doi: 10.1016/S1474-4422(12)70264-8 – ident: e_1_2_8_90_1 doi: 10.1016/j.gaitpost.2012.10.027 – ident: e_1_2_8_103_1 doi: 10.1016/j.parkreldis.2012.10.004 – ident: e_1_2_8_44_1 doi: 10.1002/mds.25380 – ident: e_1_2_8_8_1 – ident: e_1_2_8_14_1 doi: 10.1002/mds.26724 – ident: e_1_2_8_97_1 doi: 10.1016/j.apmr.2012.07.028 – ident: e_1_2_8_18_1 doi: 10.1002/ana.410420221 – ident: e_1_2_8_101_1 doi: 10.1016/S1474-4422(14)70055-9 – ident: e_1_2_8_149_1 doi: 10.1002/mds.22782 – volume: 3 start-page: 2 year: 2012 ident: e_1_2_8_4_1 article-title: Guidelines for treatment Parkinson's disease. Part 1: Motor symptoms publication-title: Journal of Neurology – ident: e_1_2_8_162_1 doi: 10.1177/0269215515570381 – ident: e_1_2_8_72_1 doi: 10.1097/NPT.0000000000000111 – ident: e_1_2_8_172_1 doi: 10.1016/S0140-6736(05)71083-7 – reference: 30578695 - Mov Disord. 2018 Dec;33(12):1992 |
| SSID | ssj0011516 |
| Score | 2.6905105 |
| SecondaryResourceType | review_article |
| Snippet | ABSTRACT
Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).... Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).... The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). The Movement... The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).OBJECTIVEThe... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1248 |
| SubjectTerms | amantadine anticholinergics Antiparkinson Agents catechol‐O‐methyl transferase inhibitors clozapine complementary therapies Deep Brain Stimulation dopamine agonists Evidence-Based Medicine exercise Humans International Cooperation levodopa monoamine oxidase inhibitors neurosurgery occupational therapy Parkinson Disease - physiopathology Parkinson Disease - therapy Parkinson's disease physical therapy Physical Therapy Modalities randomized controlled trial Societies, Scientific - standards speech therapy |
| Title | International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.27372 https://www.ncbi.nlm.nih.gov/pubmed/29570866 https://www.proquest.com/docview/2018027494 |
| Volume | 33 |
| WOSCitedRecordID | wos000448866400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1531-8257 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011516 issn: 0885-3185 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3BTtwwEB3BgiouhUJLty1oWiGVy5bEG8dxe0LAikNBCFhpb5GdOBISm6zIUqk3PoFzP69f0nHsDVpBJSRuUeLYljOTeePxvAHYEYLcHk3CGxrSpkhHMelcmPc0l2FGFjwxyhWbEKenyWgkzxbgxywXxvFDtBtuVjOa_7VVcKXrvQfS0HFef2O2yMoiLDGSW96BpcPzwfBnG0QgYxY7EMmbJOEZsVDA9tqX583RI4w5D1kbmzNYfdFs1-C1h5q472TjDSyYch1enfhg-jqsnvlvhJeOWmAD_sxtEKJNiW6yw1CVOY6rhlt8irln7MTaHflE40uT_r27t1aRmvpB0GXGfMfhxO4sIPXUnmyvkfAyEv6kjsnxx_r3eDKtxjVWxcPAX2v0IaS3MBwcXR4c93z1hl7WlyHrKcNVLI0yQpERzEId6ZgFnG7GOuyrsGARN0IWnHxMQjmBEEWSR4khRBeYgmDTO-iUVWneA7LQCBFkeVaIKOK51Ib147yfJUVsmJa6C7uzj5hmntrcVti4Th0pM0tp-dNm-bvwpW06cXweTzX6PJOElLTNhlBUaapbemz5zsiRl1EXNp2ItN0wyQU5iDHNppGE__efnhxeNBcfnt_0I6zYwd3Zw0_Qmd7cmi1Yzn5Nr-qbbVgUo2TbK8A_NHsLBw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Rb9MwED6NDrG9MBgbKzB2oEnspVviOnGMeEHbqk201cRaaW9RnDjSJJpUS4vEGz-BZ34ev4Rz7GaqNqRJvEWJ41j2Xe47n-87gH0hyO1RJLy-Jm3iioekc37WUYH0U7LgkU5ssQkxHEZXV_JiBT4tcmEsP0Sz4WY0o_5fGwU3G9JHt6yhk6w6ZKbKyiNY5SRGJN-rJ197434TRSBrFloUGdRZwgtmIY8dNS8v26M7IHMZs9ZGp7fxf8N9Bk8d2MTPVjqew4ouNuHJwIXTN2Hjwq0Sjiy5wAv4vbRFiCYpus4Pw6TIcFLW7OIzzBxnJ1b20CdqV5z0z89fxi5SU_cRtLkxH3E8NXsLSD01Z9srJMSMhECpY3L9sfoxmc7KSYVlfvvhDxW6INIWjHuno-Ozjqvf0Em70medRAdJKHWiRUJmMPUVVyHzAroZKr-b-DnjgRYyD8jLJJzjCZFHGY80YTpP5wSctqFVlIXeAWS-FsJLszQXnAeZVJp1w6ybRnmomZKqDQeLVYxTR25uamx8iy0tM4tp-uN6-tvwvmk6tYwe9zV6txCFmPTNBFGSQpdzemwYz8iVl7wNL62MNN0wGQhyEUMaTS0K_-4_Hpxc1hevHt50D9bORoN-3D8ffnkN62Yg9iTiG2jNbuZ6Fx6n32fX1c1bpwd_AdRPDg8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9swED-6dJS9rF33p-nW7TYG20taW5Eta_SlNAsba0PYGuibsSwZBo0d6nTQt36EPvfj9ZPsZCkuYSsM9mZsWRbSne93Ot3vAN4LQW6PIuENDWkTVzwmnQt1T0UyzMmCJyZzxSbEaJScnsrxCuwvcmEcP0S74WY1o_lfWwU3M13s3bGGTnW9y2yVlQewym0RmQ6sDr4PJ0dtFIGsWexQZNRkCS-YhQK21768bI_-AJnLmLUxOsP1_xvuBjz2YBMPnHQ8gRVTbsLasQ-nb8L62K8Snjhygadws7RFiDYpuskPw6zUOK0advE5as_ZibU79InGFye9vbq2dpGa-o-gy435hJOZ3VtA6qk9214jIWYkBEodk-uP9eV0Nq-mNVbF3Yc_1OiDSM9gMvx8cvil5-s39PK-DFkvM1EWS5MZkZEZzEPFVcyCiG7GKuxnYcF4ZIQsIvIyCecEQhSJ5okhTBeYgoDTc-iUVWm2AFlohAhynReC80hLZVg_1v08KWLDlFRd-LhYxTT35Oa2xsZZ6miZWUrTnzbT34V3bdOZY_T4W6O3C1FISd9sECUrTXVBjy3jGbnyknfhhZORthsmI0EuYkyjaUTh_v7T48GP5mL735u-gbXxYJgefR19ewmP7DjcQcRX0JmfX5gdeJj_mv-sz197NfgNTIwNig |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+Parkinson+and+movement+disorder+society+evidence%E2%80%90based+medicine+review%3A+Update+on+treatments+for+the+motor+symptoms+of+Parkinson%27s+disease&rft.jtitle=Movement+disorders&rft.au=Fox%2C+Susan+H.&rft.au=Katzenschlager%2C+Regina&rft.au=Lim%2C+Shen%E2%80%90Yang&rft.au=Barton%2C+Brandon&rft.date=2018-08-01&rft.issn=0885-3185&rft.eissn=1531-8257&rft.volume=33&rft.issue=8&rft.spage=1248&rft.epage=1266&rft_id=info:doi/10.1002%2Fmds.27372&rft.externalDBID=10.1002%252Fmds.27372&rft.externalDocID=MDS27372 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |